WO1997003106A1 - Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications - Google Patents
Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications Download PDFInfo
- Publication number
- WO1997003106A1 WO1997003106A1 PCT/US1996/011261 US9611261W WO9703106A1 WO 1997003106 A1 WO1997003106 A1 WO 1997003106A1 US 9611261 W US9611261 W US 9611261W WO 9703106 A1 WO9703106 A1 WO 9703106A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peg
- poly
- ppm
- group
- thiol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
Definitions
- the invention relates to derivatives of poly(ethylene glycol) and related hydrophilic polymers, to methods for their synthesis, and to surfaces and molecules modified by these polymers for biotechnical use.
- PEG poly(ethylene glycol)
- PEO poly(ethylene oxide)
- alpha-, omega-dihydroxy1 poly(ethylene glycol) can be represented in brief form as HO-PEG-OH where it is understood that the -PEG- sy bol represents the following structural unit:
- PEG is soluble in organic solvents.
- PEG attached to enzymes can result in PEG-enzyme conjugates that are soluble and active in organic solvents. Attachment of PEG to protein can reduce the immunogenicity and rate of kidney clearance of the PEG-protein conjugate as compared to the unmodified protein, which may result in dramatically increased blood circulation lifetimes for the conjugate.
- PEG attached to surfaces can reduce protein and cell adsorption to the surface and alter the electrical properties of the surface.
- PEG attached to liposomes can result in a great increase in the blood circulation lifetime of these particles and thereby possibly increase their utility for drug delivery.
- Harris J.M. Harris, Ed., "Biomedical and Biotechnical Applications of Polyethylene Glycol Chemistry, " Plenum, New York, 1992) .
- Chemically active or "activated" derivatives of the PEG polymer are prepared to attach the PEG to molecules and surfaces.
- a number of such derivatives have been prepared, some of which are of somewhat general utility, some of which are directed to solving specific problems associated with particular applications, and some of which have not proved useful or have problems that limit their usefulness.
- active esters of alpha-, omega-dicarboxylic acids of PEG have been prepared, typically for attachment of PEG to amino groups .
- an active ester is poly(ethylene glycol) di - succinimidyl succinate (symbolized in shorthand as "SS- PEG-SS”) : H0 2 C-CH 2 CH 2 - C0 2 -PEG-0 2 C- CH 2 CH 2 - C0 2 -H + 2NHS -OH ⁇ ⁇ NHS-0 2 C-CH 2 CH 2 - C0 2 - PEG-0 2 C- CH 2 CH 2 - C0 2 -NHS
- N-hydroxy succinimide from which the succinimidyl active ester moiety is derived.
- N-hydroxylsuccinimide active ester moiety will be represented as -C0 2 -NHS.
- the SS-PEG-SS active ester reacts rapidly with amino groups on proteins and other molecules to form a stable amide linkage (-C0-NH-) .
- a problem with the active ester is that SS-PEG-SS possesses ester linkages in the backbone that remain intact after coupling to an amine such as a protein (represented as PRO-NH 2 ) :
- the intact ester linkage that remains after the protein and PEG conjugate is formed is subject to hydrolysis.
- the PEG detaches from the modified protein in aqueous solution.
- the rate at which hydrolysis occurs can vary with the environment .
- U.S. Patent No. 4,670,417 discloses hemoglobin modified with various dicarboxylic acid PEGs in which the ester linkage that would otherwise remain in the conjugate is replaced with an ether linkage.
- the hemoglobin is modified in the presence of amino acids or amines that are said to also react with the dicarboxylic acid PEG to prevent excessive carboxyl groups from reacting with the hemoglobin, to avoid crosslinking and gelation of the reaction mixture, and to avoid the time, expense, and use of large reaction vessels that would otherwise be required.
- special precautions are necessary to prevent cross linking with this difunctional material.
- PEGs that are activated at each terminus with the same reactive moiety have been referred to in the art as being "homobifunctional" to indicate that the active moieties at the polymer ends are normally the same.
- PEG derivatives in which different functional groups are present at the two terminae of the polymer chain. These derivatives are sometimes referred to as heterobifunctional or heterofunctional .
- PEG derivatives active on one end and capped on the opposite end by a relatively nonreactive methoxy group have been prepared. These mPEGs are typically considered to be monofunctional, so that only one end of the PEG is active for conjugation to other substances. For example, one PEG is frequently used in a form in which there is a relatively nonreactive methoxy group at one terminus and the reactive succinimidyl succinate group at the other terminus :
- the invention is based upon the recognition that many of the activated carboxylic acid PEGs have poor reactivity and are either too slow or too fast to be generally useful for conjugation.
- the NHS ester of carboxymethylated PEG is so reactive that it hydrolyzes almost immediately upon solution in water. This high reactivity is a serious deficiency of PEG derivatives based on carboxymethylated PEG.
- the invention provides heterofunctional and monofunctional PEGs and related polymers having a single carboxylic acid moiety of suitable reactivity, which can be activated.
- the active esters of these polymer acids have a single active ester and no other ester linkages.
- the active esters have a half life in water of from about 10 to 25 minutes.
- These esters include either a propionic or butanoic acid moiety and a polymer such as PEG or a related polymer.
- These related polymers include poly(alkylene oxides) , poly(oxyethylated polyols), poly(olefinic alcohols) , and poly(acrylomorpholine) .
- conjugates of these activated polymers with biologically active substances such as polypeptides, proteins, enzymes, phospholipids, lipids, liposomes, nucleosides, oligonucleotides, drugs, dyes, and the surfaces of solid materials that are compatible with living organisms, tissue, or fluids, which are sometimes referred to as biomaterials. Further provided are methods for preparation of these activated polymers and conjugates.
- one terminus of PEG is the activated propionic acid or butanoic acid moiety and the other terminus can be capped with a relatively nonreactive methoxy group, for example, or can be activated with any other functional group, which may be protected or unprotected.
- the succinimidyl ester of heterofunctional PEG propionic acid can be represented as follows :
- X- can include any activating group other than a carboxylic acid or activated carboxylic acid or can be a relatively nonreactive group such as methoxy, CH 3 0- .
- "X-" can include the thiol-selective vinyl sulfone and other sulfone moieties as shown in commonly assigned U.S. Patent No. 5,446,090, which issued on August 29, 1995, the contents of which are incorporated herein by reference.
- the utility of the heterofunctional and monofunctional propionic and butanoic acid PEGs is believed to come from four sources.
- succinimidyl ester of PEG propionic acid has ideal reactivity for attachment to amines, such as proteins, in aqueous solution.
- the succinimidyl ester of PEG butanoic acid is less reactive than the propionic acid, but is still of utility.
- the reactions at the terminae of the heterofunctional and monofunctional PEG molecules can be controlled to limit cross linking generally more easily than typically is true of homobifunctional derivatives.
- the hydrolytic stability of the ether linkages in the backbone of PEG propionic acid results in stable conjugates after chemical coupling to another molecule or surface.
- the hydrolytic stability of the ether linkage in the intermediate heterofunctional and monofunctional propionic acid PEGs permits ready purification of the intermediate by ion exchange chromatography in aqueous medium.
- the structure of the active esters of poly(ethylene glycol) of the invention can be represented as follows :
- the moiety (OCH 2 CH 2 ) n represents PEG wherein n is from about 20 to 4000. More typically, n is from 20 to
- Z is selected from hydrolytically stable groups including -O- , -S-, -NHCO-, -CONH-,
- m is from 2 to 3 for propionic and butanoic acid derivatives, respectively.
- Q is selected from the group including hydrogen, tert- butyl, N-succinimide, N-sulfosuccinimide, N-phthalimide, N-glutarimide, N-tetrahydrophthalimide, N-norbornene-2, 3-dicarboximide, hydroxybenzotriazole, and hydroxy-7-azabenzotriazole.
- the invention provides active esters that have suitable reactivity for modification of other molecules and surfaces. Use of these
- Example 1 Synthesis of CH 3 0- (CH 2 CH 2 0) n -CH 2 CH 2 C0 2 -NHS
- Example 2 Synthesis of CH 3 0- (CH 2 CH 2 0) n -CH 2 CH 2 -S- CH 2 CH 2 C0 2 -NHS
- Example 3 Synthesis of CH 3 0- (CH,CH 2 0) n -CH 2 CH 2 CH 2 C0 2 -NHS
- Example 4 - Rates of hydrolysis of PEG-NHS active esters
- Example 5 Synthesis of HO- (CH-,CH 2 0) n -CH 2 CH 2 -S-CH 2 CH 2 -C0 2 H
- Example 6 Synthesis of HO- (CH 2 CH 2 0) n -CH 2 CH 2 -S-CH 2 CH 2
- Example 14 Synthesis of (CH 3 ) -C-O-CONH- (CH 2 CH 2 0) n -CH 2 CH 2 C00H
- Example 15 - ⁇ -methoxy- ⁇ -dipalmitoylphos- phatidylethanolamide of propionic acid of PEG (a"PEG-phospholipid)
- Example 16 - ⁇ -methoxy- ⁇ -distearoyl- phosphatidylethanolamide of propionic acid of PEG (a "PEG"-phospholipid)
- Example 17 Synthesis of HS-CH 2 CH 2 CONH- (CH 2 CH 2 0) n -CH 2 CH 2 -S-CH 2 CH 2 C0 2 H
- Example 18 Coupling of methoxy-PEG-SPA to glass surfaces
- Example 19 Coupling of PEG-SPA to proteins
- M-PEG-5000-methanesulfonate from Shearwater Polymers, 70.0 g; 0.0206 moles was added to a mixture of 280 ml toluene and 420 ml absolute ethanol and stirred to dissolve.
- Ethyl-3-mercaptopropionoate (3x excess; 7.84 ml; 8.15 g; 0.061 moles) was added to -li ⁇ the reaction via syringe and the reaction was heated under a nitrogen atmosphere to 60°C for three hours. The reaction mixture was cooled to room temperature, filtered to remove insoluble salts and concentrated to about 250 ml under reduced pressure. This is added to 1200 ml cold diethyl ether, giving a pale yellow precipitate which is dried in vacuo overnight .
- M-PEG-5000-S-CH 2 CH 2 -COOC 2 H S from the preceding step (70.0 g; 0.0206 moles) was added to 840 ml distilled deionized water and stirred to dissolve.
- sodium hydroxide (1.4 g) was added to 35 ml distilled deionized water and stirred to dissolve.
- the sodium hydroxide solution was added to the PEG solution until the pH was 12-13.
- the solution was then stirred at room temperature for one hour.
- Oxalic acid was added to adjust the pH to 3.
- the solution was extracted with CH 2 C1 2 three times (200/200/200 ml) .
- M-PEG-5000-COOH from the preceding step (3.00 g; 0.8823 mmol)
- N,N' dicyclohexyl carbodiimide 1.5x excess; 0.2731 g; 0.001324 mmol
- N-hydroxysuccinimide 1.5x excess; 0.1523 g; 0.001324 mmol
- M-PEG methanesulfonate (20 g, 1 equivalent, MW 5000 daltons, from Shearwater Polymers) was dissolved in 50 ml of toluene and added to the above mixture. The resulting mixture was reflexed overnight. The reaction mixture was then concentrated to half its original volume, extracted with 15 ml of 10% aqueous NaCl solution, extracted with 10 ml of 1% aqueous hydrochloric acid, and the aqueous extracts combined. The collected aqueous layers were extracted with dichloromethane (50 ml x 3) , and the organic layer was dried with magnesium sulfate for 3 hours, filtered, and evaporated to dryness. Yield: 20 g of PEG malonic ester.
- M-PEG malonic ester (18 g) was dissolved in 240 ml of IN sodium hydroxide containing 12 g of sodium chloride, and the mixture was stirred for one hour.
- M-PEG malonic acid (15 g) was dissolved in 120 ml of dioxane and refluxed for 8 hours, then concentrated to dryness. The residue was dissolved in 100 ml water, extracted with dichloromethane (70 ml and 50 ml) , dried over magnesium sulfate, and the solution concentrated by rotary evaporation. The residue was precipitated by addition to cold diethyl ether. Yield: 11 g.
- SCM-PEG (10) has a half life of 0.75 minutes and reacts with water too quickly to be useful for conjugation with biologically active substances or surfaces.
- SS-PEG (6) with a half life of 9.8 minutes, has good reactivity, but contains an ester linkage and forms hydrolytically unstable conjugates.
- SSPA-PEG (5) which is prepared in accordance with the present invention, has good reactivity and no ester linkage that could interfere with hydrolytic stability of conjugates.
- SPA-PEG (4) has ideal reactivity at a half life of 16.5 minutes and no ester linkage that could interfere with hydrolytic stability. SBA-PEG (1) reacts more slowly, at a half life of 23.3 minutes, but still is of utility. Generally, a half life of 10 to about 20 or 25 minutes is desirable.
- PEG-3400-methanesulfonate (70.0 g; 11% substituted; 0.0206 moles, Shearwater Polymers) was added to a mixture of 280 ml toluene and 420 ml absolute ethanol and stirred to dissolve.
- Sodium hydroxide (3x excess; 2.32 g; 0.0581 moles) was dissolved in 56 ml absolute ethanol and added to the PEG-mesylate.
- Ethyl-3- mercaptopropionoate (3x excess; 7.84 ml; 8.15 g; 0.0607 moles) was added to the reaction via syringe and the reaction was heated under a nitrogen atmosphere to 60°C for three hours.
- the reaction mixture is cooled to room temperature, filtered to remove insoluble salts and concentrated to about 250 ml under reduced pressure. This is added to 1200 ml cold diethyl ether, giving the desired ester as a pale yellow precipitate which is dried in vacuo overnight .
- the extract was dried over Na 2 S0 4 /MgS0 4 , filtered, concentrated under reduced pressure to about 150 ml and added to 1000 ml cold diethyl ether to precipitate the product .
- the product was dried in vacuo overnight . Yield: 61.6 g, 88%.
- the mixture was purified by ion exchange chromatography on Sepharose FF (Pharmacia) .
- -NMR DMSO-d 2.63 ppm (m, -SCH 2 CH 2 -, 4H) , 3.50 ppm (s, PEG backbone, 304H) , 4.57 ppm (t, OH, IH) .
- CH 2 CH-C0 2 - (CH 2 CH 2 0) n CH 2 CH 2 S-CH 2 CH 2 -C0 2 -NHS
- this product (0.946 g; 0.278 mmol), N,N' dicyclohexyl carbodiimide (1.5x excess; 0.0861 g; 0.417 mmol) and N-hydroxysuccinimide (1.5x excess; 0.0480 g; 0.417 mmol) were dissolved in 30.0 ml CH 2 C1 2 .
- the flask was immersed in an ice bath and stirred overnight. The next day the reaction mixture was filtered, concentrated under reduced pressure, filtered and precipitated into cold diethyl ether. Yield 0.592 g., 63%.
- the reaction was heated to reflux and the methanol was collected in the Dean- Stark trap along with an additional 8 ml solvent.
- the reaction mixture was cooled under nitrogen to room temperature, during which time the color changed from pale yellow to deep red-brown. Allyl chloride (1.35 g; 1.43 ml; 0.00176 moles) was added via syringe and the mixture was stirred overnight at room temperature. The following morning the mixture was filtered through a buchner funnel, concentrated under reduced pressure and precipitated into cold ether. Yield 49.17 g, 82%.
- the isolated product was checked by NMR to confirm that substitution had occurred.
- allyl-PEG 3400 (49.17 g; 0.0144 moles) was dissolved in 250 ml toluene and azeotropically dried approximately 15 minutes to remove 15 ml cloudy solvent/water.
- Polymers 100 . 0 g ; 0 . 0281 moles ) was added to a mixture of 400 ml toluene and 300 ml absolute ethanol and stirred to dissolve .
- Ethyl - 3 -mercaptopropionate ( 6 . 0 g; 0.0445 moles. 79.2% of stoichiometric amount) and sodium hydroxide (1.6 g; 0.04 moles, 71.1% of stoichiometric amount) dissolved in 40 ml absolute ethanol were added to the reaction mixture.
- the reaction was heated under nitrogen atmosphere at 60°C for three hours.
- the reaction mixture was cooled to room temperature, filtered to remove insoluble salt and concentrated to about 300 ml under reduced pressure.
- the reaction product (mixture of a , ⁇ - diamino of PEG, ⁇ -amino- ⁇ -thiopropionic acid of PEG, and ⁇ , ⁇ -dithiopropionic acid of PEG) was extracted with dichloromethane (3 X 300 ml) . The extract was dried over anhydrous magnesium sulfate, filtered and concentrated to dryness. Pure ⁇ -amino-hydrochloride- ⁇ - thiopropionic acid of PEG was separated by ion exchange chromatography on S-Sepharose FF (Pharmacia) . Yield 37.5 g.
- EXAMPLE 12 alpha-amino, omega-propionic acid of PEG H 2 NCH 2 CH 2 0 ( CH 2 CH 2 0 ) n CH 2 CH 2 C0 2 H
- the pH of the solution was maintained with periodical addition of 0.1 N sodium hydroxide.
- the solution was added to the mixture of 160 ml concentrated ammonium hydroxide and 16 g ammonium chloride and stirred 46 hours at room temperature.
- the reaction product was extracted with dichloromethane (3 X 50 ml) .
- the extract was washed with 20 ml 1 M hydrochloric acid, 20 ml distilled water and dried with anhydrous sodium sulfate.
- the solvent was distilled under reduced pressure giving 4.2 g of ex ⁇ amine hydrochloride- ⁇ -propionic acid of PEG.
- ⁇ -Methoxy- ⁇ -propionic acid succinimidyl ester of PEG of molecular weight 2170 (MSPA) (10 g, 0.00461 moles) was dissolved in chloroform (40 ml) and treated with solid distearoylphosphatidylethanolamine (DSPE) (3.72 g, 0.00497 moles) and triethylamine (2.4 ml) .
- MSPA molecular weight 2170
- DSPE solid distearoylphosphatidylethanolamine
- triethylamine 2.4 ml
- PEG amino acid ( ⁇ -aminohydrochloride- ⁇ -S- propionic acid, from Example 10) (1.83 grams) of molecular weight 400 was dissolved in 250 ml of benzene containing 1.0 ml of triethylamine and 20 ml of dry methylene chloride. Benzene was distilled off under reduced pressure. The residue was redissolved in 10 ml of acetonitrile, and succinimidyl-3- (2- pyridyldithio)propionate (SPDP) dissolved in 10 ml of acetonitrile was added. The mixture was stirred at room temperature under nitrogen atmosphere overnight . Gel permeation chromatography showed no aminoacid peak and a new monoacid peak. The solvent was distilled off under reduced pressure. Yield 3.2 g.
- the product from the preceding step (3.2 g) was dissolved in 300 ml of distilled water containing 2.5 g of dithiothreitol and stirred at room temperature under nitrogen atmosphere for 3 hours .
- the reaction mixture was applied to a DEAE Sepharose FF column (100 ml) , and the column was washed with 800 ml of distilled water.
- the product was eluted with 200 ml of 0.5 M NaCl .
- the pH of the eluate was adjusted to 3.0 with
- Quartz slides were cleaned and activated for surface modification by soaking in 1% (w/w) aqueous NaOH at 90°C for 10 minutes, 3% (w/w) HCl at 90°C for 10 minutes, and boiling in 30% (w/w) H 2 0 : for 1 hour to remove trace organics, then rinsed with water.
- the clean glass slides were prepared for functionalization with aminopropylsilane by drying under vacuum of IO "3 torr for 1 hour to remove excess surface water.
- the glass slides were then exposed to a 2% (v/v) solution of silane in anhydrous toluene for 4 hours at room temperature.
- the capillaries were rinsed with toluene and cured in a vacuum oven at 190°C, IO" 3 torr for 12 hours. This procedure gave quartz slides with available amino groups on the surface.
- Methoxy-PEG-SPA from Example 1 was grafted to the functionally activated quartz surfaces by reacting as 5% (w/v) solution in 0.05 M sodium bicarbonate (pH 8.3) for 4 hours at 40°C. After PEG immobilization, surfaces were rinsed with toluene, dried under vacuum and rinsed with water. Examination with X-ray photoelectron spectroscopy (XPS) showed the presence of a large C-0 peak consistent with attachment of PEG. Also the water-contact angle is near zero, as expected for a PEG-coated surface. Finally, adsorption studies with fibrinogen revealed that fibrinogen adsorption on the PEG-coated surface has been reduced by approximately 98% relative to uncoated quartz.
- XPS X-ray photoelectron spectroscopy
- PEG-SPA Succinimidyl esters of PEG propionic acids
- the enzyme subtilisin (2 ml of a 2.37 mg/ml solution) was coupled to acryloyi-PEG-SPA (from Example 7) (MW 3400, 10 mg) by reaction in 2 ml of borate buffer (0.1 M, pH 8.0) for one hour at 4°C.
- the protein was purified by ultrafiltration with an Amicon PM 30 ultrafiltration membrane. Analysis with fluorescamine assay showed that two lysine groups had been modified by PEG attachment.
- bovine alkaline phosphatase MW 140,000 was coupled to methoxy-PEG- SPA, MW 5000, (from Example 1) by reaction of 20 mg of enzy e and 30 mg of the PEG in 2 ml of buffer containing 0.2 M sodium phosphate and 0.5 M NaCl (pH 7.5) at 4°C for 30 minutes. Unreacted PEG was removed by ultrafiltration, as above. Fluorescamine analysis showed that 20% of the available lysines were modified. Analysis on size exclusion chromatography (Toya Soda TSK 3000 column with pH 7 phosphate buffer eluent) showed that the molecular weight of the PEG-protein conjugate was approximately 30 thousand daltons greater than that of native protein.
- These other polymers include poiy(vinyl alcohol) (“PVA”) ; other poly(alkylene oxides) such as poly(propylene glycol) (“PPG”) and the like; and poly(oxyethylated polyols) such as poly(oxyethylated glycerol) , poly(oxyethylated sorbitol) , and poly(oxyethylated glucose) , and the like.
- PVA poiy(vinyl alcohol)
- PPG poly(propylene glycol)
- poly(oxyethylated polyols) such as poly(oxyethylated glycerol) , poly(oxyethylated sorbitol) , and poly(oxyethylated glucose) , and the like.
- the polymers can be homopolymers or random or block copolymers and terpolymers based on the monomers of the above polymers, straight chain or branched, or substituted or unsubstituted similar to mPEG and other capped, monofunctional PEGs having a single active site available for attachment to a linker.
- suitable additional polymers include poly(oxazoline) , poly(acryloylmorpholine) (“PAcM”) as described in published Italian Patent Application MI-92-A-0002616 filed November 17, 1992, and poly(vinylpyrrolidone) (“PVP”) .
- PVP and poly(oxazoline) are well known polymers in the art and their preparation and use in the syntheses described above for mPEG should be readily apparent to the skilled artisan.
- the invention has been described with respect to several particular examples and embodiments. However, the foregoing examples and description are not intended to limit the invention to the exemplified embodiments, and the skilled artisan should recognize that variations can be made within the scope and spirit of the invention as described in the foregoing specification. The invention includes all alternatives, modifications, and equivalents that may be included within the true scope and spirit of the invention as defined by the appended claims.
Landscapes
- Chemical & Material Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Polyethers (AREA)
Abstract
Description
Claims
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU63457/96A AU6345796A (en) | 1995-07-07 | 1996-07-03 | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49932195A | 1995-07-07 | 1995-07-07 | |
| US08/499,321 | 1995-07-07 | ||
| US08/642,231 | 1995-10-02 | ||
| US08/642,231 US5672662A (en) | 1995-07-07 | 1995-10-02 | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1997003106A1 true WO1997003106A1 (en) | 1997-01-30 |
Family
ID=27053119
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1996/011261 Ceased WO1997003106A1 (en) | 1995-07-07 | 1996-07-03 | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US5672662A (en) |
| AU (1) | AU6345796A (en) |
| WO (1) | WO1997003106A1 (en) |
Cited By (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999045964A1 (en) * | 1998-03-12 | 1999-09-16 | Shearwater Polymers, Incorporated | Poly(ethylene glycol) derivatives with proximal reactive groups |
| WO2001026692A1 (en) * | 1999-10-08 | 2001-04-19 | Shearwater Corporation | Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation |
| WO2001046291A1 (en) * | 1999-12-22 | 2001-06-28 | Shearwater Corporation | Sterically hindered derivatives of water soluble polymers |
| WO2002049673A2 (en) | 2000-12-20 | 2002-06-27 | F. Hoffmann-La Roche Ag | Conjugates of erythropoietin (pep) with polyethylene glycol (peg) |
| US6448369B1 (en) | 1997-11-06 | 2002-09-10 | Shearwater Corporation | Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation |
| WO2003005026A3 (en) * | 2001-07-02 | 2003-06-26 | Amersham Biosciences Uk Ltd | Chemical capture reagent |
| WO2004000366A1 (en) | 2002-06-21 | 2003-12-31 | Novo Nordisk Health Care Ag | Pegylated factor vii glycoforms |
| WO2004012773A1 (en) | 2002-07-24 | 2004-02-12 | F. Hoffmann-La Roche Ag | Polyalkylene glycol acid additives |
| WO2004022629A3 (en) * | 2002-09-09 | 2004-04-08 | Nektar Therapeutics Al Corp | Method for preparing water-soluble polymer derivatives bearing a terminal carboxylic acid |
| WO2004061094A1 (en) | 2002-12-30 | 2004-07-22 | Gryphon Therapeutics, Inc. | Water-soluble thioester and selenoester compounds and methods for making and using the same |
| WO2005037214A2 (en) | 2003-10-14 | 2005-04-28 | Intermune, Inc. | Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication |
| EP1423093A4 (en) * | 2001-04-23 | 2005-11-30 | Wisconsin Alumni Res Found | MODIFIED HYDROGELS BIFUNCTIONAL |
| WO2006009901A2 (en) | 2004-06-18 | 2006-01-26 | Ambrx, Inc. | Novel antigen-binding polypeptides and their uses |
| US7118737B2 (en) | 2000-09-08 | 2006-10-10 | Amylin Pharmaceuticals, Inc. | Polymer-modified synthetic proteins |
| US7128913B2 (en) | 2000-12-20 | 2006-10-31 | Hoffmann-La Roche Inc. | Erythropoietin conjugates |
| WO2006134173A2 (en) | 2005-06-17 | 2006-12-21 | Novo Nordisk Health Care Ag | Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine |
| WO2007022780A1 (en) * | 2005-08-26 | 2007-03-01 | Novo Nordisk A/S | A method of modifying a macromolecular system |
| WO2008030558A2 (en) | 2006-09-08 | 2008-03-13 | Ambrx, Inc. | Modified human plasma polypeptide or fc scaffolds and their uses |
| US7407973B2 (en) | 2003-10-24 | 2008-08-05 | Intermune, Inc. | Use of pirfenidone in therapeutic regimens |
| EP1982732A2 (en) | 2000-02-11 | 2008-10-22 | Maxygen Holdings Ltd. | Factor VII or VIIA-like molecules |
| EP2045282A1 (en) * | 2005-08-26 | 2009-04-08 | Novo Nordisk A/S | A method of modifying a macromolecular system |
| WO2009067636A2 (en) | 2007-11-20 | 2009-05-28 | Ambrx, Inc. | Modified insulin polypeptides and their uses |
| EP2080771A2 (en) | 2001-02-27 | 2009-07-22 | Maxygen Aps | New interferon beta-like molecules |
| WO2009093713A1 (en) * | 2008-01-25 | 2009-07-30 | Ebara Corporation | Peg-modified hydroxyapatite, pharmaceutical preparation containing the same as base material, and method for production of the same |
| EP2093235A1 (en) | 2006-02-08 | 2009-08-26 | Alios Biopharma Inc. | Hyperglycosylated variants of interferon alfacon-1 |
| US7608663B2 (en) | 2004-01-21 | 2009-10-27 | Nektar Therapeutics | Method of preparing propionic acid-terminated polymers |
| US7632823B2 (en) | 2005-08-18 | 2009-12-15 | Ambrx, Inc. | Compositions of tRNA and uses thereof |
| EP2133098A1 (en) | 2000-01-10 | 2009-12-16 | Maxygen Holdings Ltd | G-CSF conjugates |
| US7638299B2 (en) | 2004-07-21 | 2009-12-29 | Ambrx, Inc. | Biosynthetic polypeptides utilizing non-naturally encoded amino acids |
| US7642323B2 (en) | 1997-11-06 | 2010-01-05 | Nektar Therapeutics | Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation |
| WO2010007626A1 (en) * | 2008-07-14 | 2010-01-21 | Biocon Limited | A method of synthesizing a substantially monodispersed mixture of oligomers |
| WO2010011735A2 (en) | 2008-07-23 | 2010-01-28 | Ambrx, Inc. | Modified bovine g-csf polypeptides and their uses |
| US7736872B2 (en) | 2004-12-22 | 2010-06-15 | Ambrx, Inc. | Compositions of aminoacyl-TRNA synthetase and uses thereof |
| EP2213733A2 (en) | 2006-05-24 | 2010-08-04 | Novo Nordisk Health Care AG | Factor IX analogues having prolonged in vivo half life |
| US7816320B2 (en) | 2004-12-22 | 2010-10-19 | Ambrx, Inc. | Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35 |
| EP2263684A1 (en) | 2003-10-10 | 2010-12-22 | Novo Nordisk A/S | IL-21 derivatives |
| EP2279756A2 (en) | 2005-04-05 | 2011-02-02 | Instituto di Ricerche di Biologia Molecolare p Angeletti S.P.A. | Method for shielding functional sites or epitopes on proteins |
| EP2284191A2 (en) | 2004-12-22 | 2011-02-16 | Ambrx, Inc. | Process for the preparation of hGH |
| US7947473B2 (en) | 2004-12-22 | 2011-05-24 | Ambrx, Inc. | Methods for expression and purification of pegylated recombinant human growth hormone containing a non-naturally encoded keto amino acid |
| EP2327724A2 (en) | 2004-02-02 | 2011-06-01 | Ambrx, Inc. | Modified human growth hormone polypeptides and their uses |
| US8012931B2 (en) | 2007-03-30 | 2011-09-06 | Ambrx, Inc. | Modified FGF-21 polypeptides and their uses |
| WO2011107591A1 (en) | 2010-03-05 | 2011-09-09 | Rigshospitalet | Chimeric inhibitor molecules of complement activation |
| WO2011143274A1 (en) | 2010-05-10 | 2011-11-17 | Perseid Therapeutics | Polypeptide inhibitors of vla4 |
| EP2390262A1 (en) | 2003-05-16 | 2011-11-30 | Intermune, Inc. | Synthetic chemokine receptor ligands and methods of use thereof |
| US8093356B2 (en) | 2005-06-03 | 2012-01-10 | Ambrx, Inc. | Pegylated human interferon polypeptides |
| US8114630B2 (en) | 2007-05-02 | 2012-02-14 | Ambrx, Inc. | Modified interferon beta polypeptides and their uses |
| WO2012024452A2 (en) | 2010-08-17 | 2012-02-23 | Ambrx, Inc. | Modified relaxin polypeptides and their uses |
| US8278418B2 (en) | 2008-09-26 | 2012-10-02 | Ambrx, Inc. | Modified animal erythropoietin polypeptides and their uses |
| WO2013006706A1 (en) | 2011-07-05 | 2013-01-10 | Bioasis Technologies Inc. | P97-antibody conjugates and methods of use |
| WO2013004607A1 (en) | 2011-07-01 | 2013-01-10 | Bayer Intellectual Property Gmbh | Relaxin fusion polypeptides and uses thereof |
| EP2548967A2 (en) | 2006-09-21 | 2013-01-23 | The Regents of The University of California | Aldehyde tags, uses thereof in site-specific protein modification |
| US8420792B2 (en) | 2006-09-08 | 2013-04-16 | Ambrx, Inc. | Suppressor tRNA transcription in vertebrate cells |
| EP2633866A2 (en) | 2003-10-17 | 2013-09-04 | Novo Nordisk A/S | Combination therapy |
| WO2013185115A1 (en) | 2012-06-08 | 2013-12-12 | Sutro Biopharma, Inc. | Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
| WO2014022515A1 (en) | 2012-07-31 | 2014-02-06 | Bioasis Technologies, Inc. | Dephosphorylated lysosomal storage disease proteins and methods of use thereof |
| WO2013189745A3 (en) * | 2012-06-18 | 2014-02-20 | Basf Se | Agroformulations containing a lactone based alkoxylate |
| WO2014036492A1 (en) | 2012-08-31 | 2014-03-06 | Sutro Biopharma, Inc. | Modified amino acids comprising an azido group |
| WO2014160438A1 (en) | 2013-03-13 | 2014-10-02 | Bioasis Technologies Inc. | Fragments of p97 and uses thereof |
| EP2805964A1 (en) | 2009-12-21 | 2014-11-26 | Ambrx, Inc. | Modified bovine somatotropin polypeptides and their uses |
| EP2805965A1 (en) | 2009-12-21 | 2014-11-26 | Ambrx, Inc. | Modified porcine somatotropin polypeptides and their uses |
| WO2015006555A2 (en) | 2013-07-10 | 2015-01-15 | Sutro Biopharma, Inc. | Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
| WO2015031673A2 (en) | 2013-08-28 | 2015-03-05 | Bioasis Technologies Inc. | Cns-targeted conjugates having modified fc regions and methods of use thereof |
| WO2015054658A1 (en) | 2013-10-11 | 2015-04-16 | Sutro Biopharma, Inc. | Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use |
| WO2015081282A1 (en) | 2013-11-27 | 2015-06-04 | Redwood Bioscience, Inc. | Hydrazinyl-pyrrolo compounds and methods for producing a conjugate |
| US9121024B2 (en) | 2008-09-26 | 2015-09-01 | Ambrx, Inc. | Non-natural amino acid replication-dependent microorganisms and vaccines |
| US9133495B2 (en) | 2006-09-08 | 2015-09-15 | Ambrx, Inc. | Hybrid suppressor tRNA for vertebrate cells |
| US9310374B2 (en) | 2012-11-16 | 2016-04-12 | Redwood Bioscience, Inc. | Hydrazinyl-indole compounds and methods for producing a conjugate |
| US9434778B2 (en) | 2014-10-24 | 2016-09-06 | Bristol-Myers Squibb Company | Modified FGF-21 polypeptides comprising an internal deletion and uses thereof |
| US9488660B2 (en) | 2005-11-16 | 2016-11-08 | Ambrx, Inc. | Methods and compositions comprising non-natural amino acids |
| EP3103880A1 (en) | 2008-02-08 | 2016-12-14 | Ambrx, Inc. | Modified leptin polypeptides and their uses |
| US9567386B2 (en) | 2010-08-17 | 2017-02-14 | Ambrx, Inc. | Therapeutic uses of modified relaxin polypeptides |
| US9579390B2 (en) | 2012-11-12 | 2017-02-28 | Redwood Bioscience, Inc. | Compounds and methods for producing a conjugate |
| EP3135690A1 (en) | 2012-06-26 | 2017-03-01 | Sutro Biopharma, Inc. | Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use |
| US9605078B2 (en) | 2012-11-16 | 2017-03-28 | The Regents Of The University Of California | Pictet-Spengler ligation for protein chemical modification |
| US9920106B2 (en) | 2003-12-18 | 2018-03-20 | Novo Nordisk A/S | GLP-1 compounds |
| US10266578B2 (en) | 2017-02-08 | 2019-04-23 | Bristol-Myers Squibb Company | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof |
| WO2019133399A1 (en) | 2017-12-26 | 2019-07-04 | Becton, Dickinson And Company | Deep ultraviolet-excitable water-solvated polymeric dyes |
| WO2019191482A1 (en) | 2018-03-30 | 2019-10-03 | Becton, Dickinson And Company | Water-soluble polymeric dyes having pendant chromophores |
| WO2020023300A1 (en) | 2018-07-22 | 2020-01-30 | Bioasis Technologies, Inc. | Treatment of lymmphatic metastases |
| WO2020056066A1 (en) | 2018-09-11 | 2020-03-19 | Ambrx, Inc. | Interleukin-2 polypeptide conjugates and their uses |
| WO2020082057A1 (en) | 2018-10-19 | 2020-04-23 | Ambrx, Inc. | Interleukin-10 polypeptide conjugates, dimers thereof, and their uses |
| WO2020168017A1 (en) | 2019-02-12 | 2020-08-20 | Ambrx, Inc. | Compositions containing, methods and uses of antibody-tlr agonist conjugates |
| WO2021183832A1 (en) | 2020-03-11 | 2021-09-16 | Ambrx, Inc. | Interleukin-2 polypeptide conjugates and methods of use thereof |
| WO2021236526A1 (en) | 2020-05-18 | 2021-11-25 | Bioasis Technologies, Inc. | Compositions and methods for treating lewy body dementia |
| WO2021255524A1 (en) | 2020-06-17 | 2021-12-23 | Bioasis Technologies, Inc. | Compositions and methods for treating frontotemporal dementia |
| WO2022040596A1 (en) | 2020-08-20 | 2022-02-24 | Ambrx, Inc. | Antibody-tlr agonist conjugates, methods and uses thereof |
| US11273202B2 (en) | 2010-09-23 | 2022-03-15 | Elanco Us Inc. | Formulations for bovine granulocyte colony stimulating factor and variants thereof |
| WO2022212899A1 (en) | 2021-04-03 | 2022-10-06 | Ambrx, Inc. | Anti-her2 antibody-drug conjugates and uses thereof |
| EP4155349A1 (en) | 2021-09-24 | 2023-03-29 | Becton, Dickinson and Company | Water-soluble yellow green absorbing dyes |
| WO2024007016A2 (en) | 2022-07-01 | 2024-01-04 | Beckman Coulter, Inc. | Novel fluorescent dyes and polymers from dihydrophenanthrene derivatives |
| WO2024044327A1 (en) | 2022-08-26 | 2024-02-29 | Beckman Coulter, Inc. | Dhnt monomers and polymer dyes with modified photophysical properties |
| WO2024196805A1 (en) | 2023-03-17 | 2024-09-26 | Beckman Coulter, Inc. | Benzothienopyrrole cyanine dyes |
| US12102689B2 (en) | 2015-11-09 | 2024-10-01 | R.P. Scherer Technologies, Llc | Anti-CD22 antibody-maytansine conjugates and methods of use thereof |
| WO2025064842A1 (en) | 2023-09-21 | 2025-03-27 | Beckman Coulter, Inc. | Dihydrophenanthrene (dhp) bridged dyes for use in flow cytometry |
| US12312437B2 (en) | 2016-04-15 | 2025-05-27 | Beckman Coulter, Inc. | Photoactive macromolecules and uses thereof |
| EP4682210A1 (en) | 2016-12-12 | 2026-01-21 | Becton, Dickinson and Company | Water-soluble polymeric dyes |
| WO2026043823A2 (en) | 2024-08-19 | 2026-02-26 | Sutro Biopharma, Inc. | Antibodies comprising site-specific non-natural amino acid residues, methods of preparation and uses thereof |
Families Citing this family (442)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020177688A1 (en) * | 1988-12-22 | 2002-11-28 | Kirin-Amgen, Inc., | Chemically-modified G-CSF |
| WO1990006952A1 (en) * | 1988-12-22 | 1990-06-28 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
| KR100361933B1 (en) | 1993-09-08 | 2003-02-14 | 라 졸라 파마슈티칼 컴파니 | Chemically defined nonpolymeric bonds form the platform molecule and its conjugate |
| US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
| US20030053982A1 (en) * | 1994-09-26 | 2003-03-20 | Kinstler Olaf B. | N-terminally chemically modified protein compositions and methods |
| US5824784A (en) * | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| US6008202A (en) * | 1995-01-23 | 1999-12-28 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US7812149B2 (en) | 1996-06-06 | 2010-10-12 | Isis Pharmaceuticals, Inc. | 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations |
| US20040266706A1 (en) * | 2002-11-05 | 2004-12-30 | Muthiah Manoharan | Cross-linked oligomeric compounds and their use in gene modulation |
| US9096636B2 (en) | 1996-06-06 | 2015-08-04 | Isis Pharmaceuticals, Inc. | Chimeric oligomeric compounds and their use in gene modulation |
| US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| US20080119427A1 (en) * | 1996-06-06 | 2008-05-22 | Isis Pharmaceuticals, Inc. | Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation |
| US7091311B2 (en) * | 1996-06-07 | 2006-08-15 | Smithkline Beecham Corporation | Peptides and compounds that bind to a receptor |
| US6214966B1 (en) * | 1996-09-26 | 2001-04-10 | Shearwater Corporation | Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution |
| US6743248B2 (en) | 1996-12-18 | 2004-06-01 | Neomend, Inc. | Pretreatment method for enhancing tissue adhesion |
| US20030191496A1 (en) * | 1997-03-12 | 2003-10-09 | Neomend, Inc. | Vascular sealing device with microwave antenna |
| US20040176801A1 (en) * | 1997-03-12 | 2004-09-09 | Neomend, Inc. | Pretreatment method for enhancing tissue adhesion |
| US6371975B2 (en) | 1998-11-06 | 2002-04-16 | Neomend, Inc. | Compositions, systems, and methods for creating in situ, chemically cross-linked, mechanical barriers |
| US6168784B1 (en) | 1997-09-03 | 2001-01-02 | Gryphon Sciences | N-terminal modifications of RANTES and methods of use |
| US20050158273A1 (en) * | 1997-09-25 | 2005-07-21 | Harris J. M. | Soluble, degradable polyethylene glycol) derivatives for controllable release of bound molecules into solution |
| US7347850B2 (en) * | 1998-08-14 | 2008-03-25 | Incept Llc | Adhesion barriers applicable by minimally invasive surgery and methods of use thereof |
| US6994686B2 (en) | 1998-08-26 | 2006-02-07 | Neomend, Inc. | Systems for applying cross-linked mechanical barriers |
| US6458147B1 (en) | 1998-11-06 | 2002-10-01 | Neomend, Inc. | Compositions, systems, and methods for arresting or controlling bleeding or fluid leakage in body tissue |
| EP1107998B1 (en) * | 1998-08-28 | 2004-02-04 | Gryphon Sciences | Method for the preparation of polyamide chains of precise length, their conjugates with proteins |
| HU229888B1 (en) | 1998-10-16 | 2014-11-28 | Biogen Idec Ma Inc Cambridge | Polymer conjugates of interferon betha-1a and uses |
| BR9915548A (en) | 1998-10-16 | 2001-08-14 | Biogen Inc | Interferon-beta fusion proteins and uses |
| US6830756B2 (en) * | 1998-11-06 | 2004-12-14 | Neomend, Inc. | Systems, methods, and compositions for achieving closure of vascular puncture sites |
| US6949114B2 (en) | 1998-11-06 | 2005-09-27 | Neomend, Inc. | Systems, methods, and compositions for achieving closure of vascular puncture sites |
| US7279001B2 (en) * | 1998-11-06 | 2007-10-09 | Neomend, Inc. | Systems, methods, and compositions for achieving closure of vascular puncture sites |
| US6899889B1 (en) | 1998-11-06 | 2005-05-31 | Neomend, Inc. | Biocompatible material composition adaptable to diverse therapeutic indications |
| US20080114092A1 (en) * | 1998-12-04 | 2008-05-15 | Incept Llc | Adhesion barriers applicable by minimally invasive surgery and methods of use thereof |
| US6458953B1 (en) * | 1998-12-09 | 2002-10-01 | La Jolla Pharmaceutical Company | Valency platform molecules comprising carbamate linkages |
| IL144361A0 (en) * | 1999-01-29 | 2002-05-23 | Hoffmann La Roche | Gcsf conjugates |
| US6270806B1 (en) | 1999-03-03 | 2001-08-07 | Elan Pharma International Limited | Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions |
| CN1762990A (en) * | 1999-06-08 | 2006-04-26 | 拉卓拉药物公司 | Valency platform molecules comprising aminooxy groups |
| CZ299516B6 (en) | 1999-07-02 | 2008-08-20 | F. Hoffmann-La Roche Ag | Erythropoietin glycoprotein conjugate, process for its preparation and use and pharmaceutical composition containing thereof |
| US7008635B1 (en) | 1999-09-10 | 2006-03-07 | Genzyme Corporation | Hydrogels for orthopedic repair |
| US6348558B1 (en) | 1999-12-10 | 2002-02-19 | Shearwater Corporation | Hydrolytically degradable polymers and hydrogels made therefrom |
| US7074878B1 (en) * | 1999-12-10 | 2006-07-11 | Harris J Milton | Hydrolytically degradable polymers and hydrogels made therefrom |
| WO2001093914A2 (en) | 2000-06-08 | 2001-12-13 | La Jolla Pharmaceutical Company | Multivalent platform molecules comprising high molecular weight polyethylene oxide |
| MXPA03000310A (en) * | 2000-07-12 | 2004-12-13 | Gryphon Therapeutics Inc | Polymer-modified bioactive synthetic chemokines, and methods for their manufacture and use. |
| KR20030057529A (en) * | 2000-09-08 | 2003-07-04 | 그리폰 테라퓨틱스, 인코포레이티드 | Synthetic erythropoiesis stimulating proteins |
| US20020065397A1 (en) | 2000-10-12 | 2002-05-30 | Joseph Roberts | Protecting therapeutic compositions from host-mediated inactivation |
| CN1507357A (en) | 2000-10-31 | 2004-06-23 | PRҩƷ����˾ | Methods and compositions for enhanced delivery of biologically active molecules |
| US7053150B2 (en) * | 2000-12-18 | 2006-05-30 | Nektar Therapeutics Al, Corporation | Segmented polymers and their conjugates |
| TW593427B (en) * | 2000-12-18 | 2004-06-21 | Nektar Therapeutics Al Corp | Synthesis of high molecular weight non-peptidic polymer derivatives |
| US9700866B2 (en) * | 2000-12-22 | 2017-07-11 | Baxter International Inc. | Surfactant systems for delivery of organic compounds |
| TWI246524B (en) * | 2001-01-19 | 2006-01-01 | Shearwater Corp | Multi-arm block copolymers as drug delivery vehicles |
| US7265186B2 (en) * | 2001-01-19 | 2007-09-04 | Nektar Therapeutics Al, Corporation | Multi-arm block copolymers as drug delivery vehicles |
| MXPA03007665A (en) * | 2001-02-26 | 2004-03-16 | Univ Duke | NEW DENDRITIC POLYMERS AND THEIR BIOMEDICAL USES. |
| US20050276858A1 (en) * | 2001-04-23 | 2005-12-15 | Kao Weiyuan J | Bifunctional-modified hydrogels |
| JP2004535388A (en) * | 2001-04-30 | 2004-11-25 | ターゲティッド ジェネティクス コーポレイション | Lipid-containing drug delivery conjugates and methods for their production |
| CA2450985A1 (en) * | 2001-06-28 | 2003-01-09 | Mountain View Pharmaceuticals, Inc. | Polymer stabilized proteinases |
| US7009033B2 (en) * | 2001-07-02 | 2006-03-07 | Polymer Source Inc. | Heterofunctional polyethylene glycol and polyethylene oxide, process for their manufacture |
| US20040077835A1 (en) * | 2001-07-12 | 2004-04-22 | Robin Offord | Chemokine receptor modulators, production and use |
| US20040208844A1 (en) * | 2001-08-01 | 2004-10-21 | Francis Ignatious | Products and drug delivery vehicles |
| US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
| ES2411007T3 (en) | 2001-10-10 | 2013-07-04 | Novo Nordisk A/S | Remodeling and glycoconjugation of peptides |
| US8008252B2 (en) | 2001-10-10 | 2011-08-30 | Novo Nordisk A/S | Factor VII: remodeling and glycoconjugation of Factor VII |
| US7157277B2 (en) | 2001-11-28 | 2007-01-02 | Neose Technologies, Inc. | Factor VIII remodeling and glycoconjugation of Factor VIII |
| US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
| ES2654819T3 (en) | 2001-10-18 | 2018-02-15 | Nektar Therapeutics | Polymeric conjugates of opioid antagonists |
| AU2002346686A1 (en) * | 2001-12-07 | 2003-06-23 | Intermune, Inc. | Compositions and method for treating hepatitis virus infection |
| PT3025726T (en) * | 2002-01-18 | 2020-01-09 | Biogen Ma Inc | POLYALKYLENE POLYMER COMPOUNDS AND USES OF THE SAME |
| US20040131582A1 (en) * | 2002-02-26 | 2004-07-08 | Grinstaff Mark W. | Novel dendritic polymers and their biomedical uses |
| CN100475269C (en) * | 2002-03-05 | 2009-04-08 | 北京键凯科技有限公司 | Binding agent of hydrophilic polymer-glutamic acid oligopeptide and medicinal molecular, composition containing said binding agent and use thereof |
| JP4272537B2 (en) * | 2002-03-13 | 2009-06-03 | 北京鍵▲凱▼科技有限公司 | Y-shaped branched hydrophilic polymer derivatives, methods for their preparation, binding products of said derivatives and drug molecules, and pharmaceutical compositions comprising said binding products |
| ES2348230T3 (en) * | 2002-06-07 | 2010-12-01 | Dyax Corp. | PREVENTION AND REDUCTION OF THE ISCHEMIA. |
| US7153829B2 (en) | 2002-06-07 | 2006-12-26 | Dyax Corp. | Kallikrein-inhibitor therapies |
| DE60336555D1 (en) | 2002-06-21 | 2011-05-12 | Novo Nordisk Healthcare Ag | PEGYLATED GLYCO FORMS OF FACTOR VII |
| ATE344289T1 (en) * | 2002-07-24 | 2006-11-15 | Hoffmann La Roche | POLYETHYLENE GLYCOL ALDEHYDE DERIVATIVES |
| WO2004013165A1 (en) * | 2002-07-24 | 2004-02-12 | F. Hoffmann-La Roche Ag | Pegylated t1249 polypeptide |
| HRP20050024A2 (en) * | 2002-07-24 | 2006-02-28 | F. Hoffmann - La Roche Ag | Pegylated t20 polypeptide |
| US7459435B2 (en) * | 2002-08-29 | 2008-12-02 | Hoffmann-La Roche Inc. | Treatment of disturbances of iron distribution |
| AU2003270118A1 (en) * | 2002-08-30 | 2004-03-19 | F. Hoffmann-La Roche Ag | Scatter factor/hepatocyte growth factor antagonist nk4 for the treatment of glioma |
| KR20050093856A (en) | 2002-09-09 | 2005-09-23 | 넥타르 테라퓨틱스 에이엘, 코포레이션 | Water-soluble polymer alkanals |
| ES2781475T3 (en) | 2002-09-18 | 2020-09-02 | Janssen Pharmaceuticals Inc | Methods to increase the production of hematopoietic stem cells and platelets |
| CA2498062C (en) * | 2002-09-27 | 2010-05-25 | F. Hoffmann-La Roche Ag | Conjugates of insulin-like growth factor binding protein-4 and poly(ethylene glycol) |
| US8129330B2 (en) * | 2002-09-30 | 2012-03-06 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
| US20040062748A1 (en) | 2002-09-30 | 2004-04-01 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
| AU2003291755A1 (en) | 2002-11-05 | 2004-06-07 | Isis Pharmaceuticals, Inc. | Oligomers comprising modified bases for binding cytosine and uracil or thymine and their use |
| TWI281864B (en) * | 2002-11-20 | 2007-06-01 | Pharmacia Corp | N-terminally monopegylated human growth hormone conjugates and process for their preparation |
| US7459436B2 (en) * | 2002-11-22 | 2008-12-02 | Hoffmann-La Roche Inc. | Treatment of disturbances of iron distribution |
| GEP20084487B (en) * | 2002-12-26 | 2008-09-25 | Mountain View Pharmaceuticals | Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof |
| JP5207590B2 (en) * | 2002-12-26 | 2013-06-12 | マウンテン ビュー ファーマシューティカルズ,インコーポレイテッド | Polymer conjugate of interferon-beta with enhanced biological ability |
| DE60322111D1 (en) | 2002-12-31 | 2008-08-21 | Nektar Therapeutics Al Co | METHOD FOR THE PRODUCTION OF HYDROGELES FROM THIOSULFONATE COMPOSITIONS AND THEIR USES |
| US20050130892A1 (en) * | 2003-03-07 | 2005-06-16 | Xencor, Inc. | BAFF variants and methods thereof |
| US20060014248A1 (en) * | 2003-01-06 | 2006-01-19 | Xencor, Inc. | TNF super family members with altered immunogenicity |
| US7553930B2 (en) * | 2003-01-06 | 2009-06-30 | Xencor, Inc. | BAFF variants and methods thereof |
| US20050221443A1 (en) * | 2003-01-06 | 2005-10-06 | Xencor, Inc. | Tumor necrosis factor super family agonists |
| KR101207247B1 (en) | 2003-01-06 | 2012-12-03 | 넥타르 테라퓨틱스 | Thiol-selective water-soluble polymer derivatives |
| US8663650B2 (en) * | 2003-02-21 | 2014-03-04 | Ac Immune Sa | Methods and compositions comprising supramolecular constructs |
| US7871607B2 (en) * | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| NZ542873A (en) * | 2003-03-05 | 2008-07-31 | Halozyme Inc | Soluble, neutral-active hyaluronidase activity glycoprotein (sHASEGP) that is produced with high yield in a mammalian expression system by introducing nucleic acids that lack a narrow region encoding amino acids in the carboxy terminus of the human PH20 cDNA |
| US20090123367A1 (en) * | 2003-03-05 | 2009-05-14 | Delfmems | Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| NZ542094A (en) | 2003-03-14 | 2008-12-24 | Neose Technologies Inc | Branched polymer conjugates comprising a peptide and water-soluble polymer chains |
| US7642340B2 (en) | 2003-03-31 | 2010-01-05 | Xencor, Inc. | PEGylated TNF-α variant proteins |
| US7587286B2 (en) * | 2003-03-31 | 2009-09-08 | Xencor, Inc. | Methods for rational pegylation of proteins |
| US7610156B2 (en) * | 2003-03-31 | 2009-10-27 | Xencor, Inc. | Methods for rational pegylation of proteins |
| US8791070B2 (en) | 2003-04-09 | 2014-07-29 | Novo Nordisk A/S | Glycopegylated factor IX |
| PL1615945T3 (en) | 2003-04-09 | 2012-03-30 | Ratiopharm Gmbh | Glycopegylation methods and proteins/peptides produced by the methods |
| DK2599502T3 (en) | 2003-04-11 | 2017-04-18 | Antriabio Inc | Process for Preparation of Site-Specific Protein Conjugates |
| EP2261244A3 (en) | 2003-04-15 | 2011-02-23 | Glaxosmithkline LLC | Human il-18 substitution mutants and their conjugates |
| JP2007523630A (en) | 2003-05-09 | 2007-08-23 | ネオス テクノロジーズ インコーポレイテッド | Composition and formulation of human growth hormone glycosylation mutants |
| CN1820024B (en) | 2003-05-12 | 2011-06-22 | 阿费麦克斯公司 | Novel poly(ethylene glycol) modified compounds and uses thereof |
| AU2004238868B2 (en) * | 2003-05-12 | 2010-01-21 | Affymax, Inc. | Peptides that bind to the erythropoietin receptor |
| US7919118B2 (en) | 2003-05-12 | 2011-04-05 | Affymax, Inc. | Spacer moiety for poly (ethylene glycol) modified peptide based compounds |
| US7459146B2 (en) | 2003-05-30 | 2008-12-02 | 3M Innovative Properties Company | Stabilized aerosol dispersions |
| US7109247B2 (en) | 2003-05-30 | 2006-09-19 | 3M Innovative Properties Company | Stabilized particle dispersions containing nanoparticles |
| US20040249119A1 (en) * | 2003-06-05 | 2004-12-09 | Fox Martin Edward | Novel mPEG propionaldehyde precursor |
| ATE460451T1 (en) * | 2003-07-22 | 2010-03-15 | Nektar Therapeutics | METHOD FOR PRODUCING FUNCTIONALIZED POLYMERS FROM POLYMERAL CARBONS |
| US9005625B2 (en) | 2003-07-25 | 2015-04-14 | Novo Nordisk A/S | Antibody toxin conjugates |
| US20050255561A1 (en) * | 2003-07-25 | 2005-11-17 | Pierre-Francois Tosi | Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers |
| US20050089515A1 (en) * | 2003-08-29 | 2005-04-28 | Dyax Corp. | Poly-pegylated protease inhibitors |
| CA2537336C (en) | 2003-09-17 | 2013-02-26 | Nektar Therapeutics Al, Corporation | Multi-arm polymer prodrugs |
| WO2005035727A2 (en) * | 2003-10-09 | 2005-04-21 | Ambrx, Inc. | Polymer derivatives |
| EP1675871A2 (en) | 2003-10-10 | 2006-07-05 | Xencor Inc. | Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders |
| WO2005042563A2 (en) * | 2003-10-22 | 2005-05-12 | Akzo Nobel N.V. | Process for incrasing protein pegylation reaction yields by diafiltration ultrafiltration |
| CA2544779A1 (en) * | 2003-11-03 | 2005-05-12 | Medtronic, Inc. | Hydrogel providing cell-specific ingrowth |
| EP1725572B1 (en) | 2003-11-05 | 2017-05-31 | AGCT GmbH | Macromolecular nucleotide compounds and methods for using the same |
| US20050214250A1 (en) | 2003-11-06 | 2005-09-29 | Harris J M | Method of preparing carboxylic acid functionalized polymers |
| US7842661B2 (en) | 2003-11-24 | 2010-11-30 | Novo Nordisk A/S | Glycopegylated erythropoietin formulations |
| US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
| US8633157B2 (en) | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
| US7189768B2 (en) * | 2003-11-25 | 2007-03-13 | 3M Innovative Properties Company | Solution containing surface-modified nanoparticles |
| US20060040856A1 (en) * | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
| US7956032B2 (en) | 2003-12-03 | 2011-06-07 | Novo Nordisk A/S | Glycopegylated granulocyte colony stimulating factor |
| WO2005058367A2 (en) | 2003-12-16 | 2005-06-30 | Nektar Therapeutics Al, Corporation | Pegylated small molecules |
| SI1696947T1 (en) * | 2003-12-19 | 2014-05-30 | F. Hoffmann-La Roche Ag | Use of erythropoietin in the treatment of disturbances of iron distribution in chronic inflammatory intestinal diseases |
| NZ548123A (en) * | 2004-01-08 | 2010-05-28 | Novo Nordisk As | O-linked glycosylation of peptides |
| US6887952B1 (en) * | 2004-02-12 | 2005-05-03 | Biosite, Inc. | N-aryl-carbamic acid ester-derived and valeric acid ester-derived cross-linkers and conjugates, and methods for their synthesis and use |
| US8569474B2 (en) | 2004-03-09 | 2013-10-29 | Isis Pharmaceuticals, Inc. | Double stranded constructs comprising one or more short strands hybridized to a longer strand |
| JP2008505853A (en) | 2004-04-13 | 2008-02-28 | クインテセンス バイオサイエンシーズ インコーポレーティッド | Non-natural ribonuclease complex as a cytotoxic agent |
| WO2005108463A2 (en) | 2004-05-03 | 2005-11-17 | Nektar Therapeutics Al, Corporation | Branched polyethylen glycol derivates comprising an acetal or ketal branching point |
| US8394947B2 (en) | 2004-06-03 | 2013-03-12 | Isis Pharmaceuticals, Inc. | Positionally modified siRNA constructs |
| WO2005123113A2 (en) * | 2004-06-14 | 2005-12-29 | Intermune, Inc. | Interferon compositions and methods of use thereof |
| US20080300173A1 (en) | 2004-07-13 | 2008-12-04 | Defrees Shawn | Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1] |
| US20060040377A1 (en) * | 2004-08-17 | 2006-02-23 | Biocept, Inc. | Protein microarrays |
| US7884086B2 (en) | 2004-09-08 | 2011-02-08 | Isis Pharmaceuticals, Inc. | Conjugates for use in hepatocyte free uptake assays |
| WO2006031583A2 (en) * | 2004-09-09 | 2006-03-23 | Biosite Incorporated | Methods and compositions for measuring canine bnp and uses thereof |
| WO2006031811A2 (en) | 2004-09-10 | 2006-03-23 | Neose Technologies, Inc. | Glycopegylated interferon alpha |
| US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
| WO2006050247A2 (en) | 2004-10-29 | 2006-05-11 | Neose Technologies, Inc. | Remodeling and glycopegylation of fibroblast growth factor (fgf) |
| WO2006062685A2 (en) * | 2004-11-11 | 2006-06-15 | Affymax, Inc. | Novel peptides that bind to the erythropoietin receptor |
| JP2008519858A (en) * | 2004-11-11 | 2008-06-12 | アフィーマックス・インコーポレイテッド | A novel peptide that binds to the erythropoietin receptor |
| EP2399893B1 (en) | 2004-12-22 | 2018-08-15 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
| EP1674113A1 (en) | 2004-12-22 | 2006-06-28 | F. Hoffmann-La Roche Ag | Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol) |
| US9029331B2 (en) | 2005-01-10 | 2015-05-12 | Novo Nordisk A/S | Glycopegylated granulocyte colony stimulating factor |
| WO2006078813A2 (en) * | 2005-01-21 | 2006-07-27 | Biosite Incorporated | Arginine analogs, and methods for their synthesis and use |
| KR100645852B1 (en) | 2005-01-22 | 2006-11-14 | 나재식 | Quenching Water Soluble Heat Treatment Oil Using Fatty Acid Graft Polyalkylene Glycol |
| US20060233740A1 (en) * | 2005-03-23 | 2006-10-19 | Bossard Mary J | Conjugates of an hGH moiety and a polymer |
| US20060222596A1 (en) | 2005-04-01 | 2006-10-05 | Trivascular, Inc. | Non-degradable, low swelling, water soluble radiopaque hydrogel polymer |
| WO2006121569A2 (en) | 2005-04-08 | 2006-11-16 | Neose Technologies, Inc. | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
| EP2975135A1 (en) | 2005-05-25 | 2016-01-20 | Novo Nordisk A/S | Glycopegylated factor IX |
| US8324159B2 (en) * | 2005-06-03 | 2012-12-04 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
| US7550433B2 (en) | 2005-06-03 | 2009-06-23 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
| US7919461B2 (en) | 2005-06-03 | 2011-04-05 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
| US8568705B2 (en) * | 2005-07-18 | 2013-10-29 | Nektar Therapeutics | Method for preparing branched functionalized polymers using branched polyol cores |
| US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
| DE102005041570A1 (en) | 2005-09-01 | 2007-03-22 | Celares Gmbh | Highly branched reagents for modifaction of biopharmaceuticals, their preparation and use |
| US20070072795A1 (en) * | 2005-09-28 | 2007-03-29 | Anton Haselbeck | Treatment of neurodegenerative disorders |
| WO2007047303A2 (en) * | 2005-10-12 | 2007-04-26 | Alvine Pharmaceuticals, Inc. | Pegylated glutenase polypeptides |
| US7687608B2 (en) * | 2005-10-19 | 2010-03-30 | Smartcells, Inc. | Methods for reducing the mitogenicity of lectin compositions |
| WO2007056191A2 (en) | 2005-11-03 | 2007-05-18 | Neose Technologies, Inc. | Nucleotide sugar purification using membranes |
| CN101400646A (en) * | 2005-11-08 | 2009-04-01 | Ambrx公司 | Promoters for modifying unnatural amino acids and unnatural amino acid polypeptides |
| WO2007070659A2 (en) * | 2005-12-14 | 2007-06-21 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
| US8431748B2 (en) * | 2006-01-16 | 2013-04-30 | Bwe I Malmo Ab | Low protonation constant hydroxy acids |
| US20070173634A1 (en) * | 2006-01-24 | 2007-07-26 | Olsson Nils U | Methods for one-step purification of organic polymers using tangential flow filtration |
| US8309680B2 (en) * | 2006-02-21 | 2012-11-13 | Nektar Therapeutics | Segmented degradable polymers and conjugates made therefrom |
| US8795709B2 (en) * | 2006-03-29 | 2014-08-05 | Incept Llc | Superabsorbent, freeze dried hydrogels for medical applications |
| US8580746B2 (en) * | 2006-03-30 | 2013-11-12 | Palatin Technologies, Inc. | Amide linkage cyclic natriuretic peptide constructs |
| EP2004633A4 (en) * | 2006-03-30 | 2009-08-26 | Palatin Technologies Inc | LINEAR CONSTRUCTIONS OF NATRIURETIC PEPTIDES |
| CA2647143A1 (en) * | 2006-03-30 | 2007-10-11 | Palatin Technologies, Inc. | Cyclic natriuretic peptide constructs |
| WO2007117685A2 (en) | 2006-04-07 | 2007-10-18 | Nektar Therapeutics Al, Corporation | Conjugates of an anti-tnf-alpha antibody |
| ES2629766T3 (en) | 2006-04-21 | 2017-08-14 | Nektar Therapeutics | Stereoselective reduction of a morfinone |
| US20100119697A1 (en) * | 2006-05-10 | 2010-05-13 | 3M Innovative Properties Company | Compositions and coatings containing fluorescent, inorganic nanoparticles |
| US7872068B2 (en) * | 2006-05-30 | 2011-01-18 | Incept Llc | Materials formable in situ within a medical device |
| WO2008002482A2 (en) * | 2006-06-23 | 2008-01-03 | Surmodics, Inc. | Hydrogel-based joint repair system and method |
| US8840882B2 (en) * | 2006-06-23 | 2014-09-23 | Quintessence Biosciences, Inc. | Modified ribonucleases |
| WO2008010991A2 (en) | 2006-07-17 | 2008-01-24 | Quintessence Biosciences, Inc. | Methods and compositions for the treatment of cancer |
| EP2049144B8 (en) | 2006-07-21 | 2015-02-18 | ratiopharm GmbH | Glycosylation of peptides via o-linked glycosylation sequences |
| CL2007002502A1 (en) | 2006-08-31 | 2008-05-30 | Hoffmann La Roche | VARIANTS OF THE SIMILAR GROWTH FACTOR TO HUMAN INSULIN-1 (IGF-1) PEGILATED IN LISIN; METHOD OF PRODUCTION; FUSION PROTEIN THAT UNDERSTANDS IT; AND ITS USE TO TREAT ALZHEIMER'S DISEASE. |
| JP4958975B2 (en) * | 2006-08-31 | 2012-06-20 | エフ.ホフマン−ラ ロシュ アーゲー | Method for producing insulin-like growth factor I |
| EP2054521A4 (en) | 2006-10-03 | 2012-12-19 | Novo Nordisk As | METHODS OF PURIFYING CONJUGATES OF POLYPEPTIDES |
| ES2655734T3 (en) | 2006-10-04 | 2018-02-21 | Novo Nordisk A/S | Glycerol glycopeptides and pegylated sugars |
| EP2118127A4 (en) * | 2007-01-31 | 2010-12-01 | Affymax Inc | NITROGEN BONDING GROUPS FOR ATTACHING MODIFIER GROUPS TO POLYPEPTIDES AND OTHER MACROMOLECULES |
| WO2008101311A1 (en) * | 2007-02-22 | 2008-08-28 | Biovectra Inc. | Process for purification of water soluble polymers |
| US20140011964A1 (en) | 2007-02-28 | 2014-01-09 | Serina Therapeutics, Inc. | Activated Polyoxazolines and Conjugates and Compositions Comprising the Same |
| EP2134181A4 (en) * | 2007-02-28 | 2011-09-28 | Serina Therapeutics Inc | ACTIVATED POLYOXAZOLINS AND COMPOSITIONS CONTAINING THEREOF |
| CN101631568B (en) | 2007-03-12 | 2012-08-22 | 尼克塔治疗公司 | Oligomer-protease inhibitor conjugates |
| EP2125027A2 (en) * | 2007-03-12 | 2009-12-02 | Nektar Therapeutics | De novo synthesis of conjugates |
| WO2008112287A1 (en) | 2007-03-12 | 2008-09-18 | Nektar Therapeutics | Oligomer-beta blocker conjugates |
| US8173666B2 (en) | 2007-03-12 | 2012-05-08 | Nektar Therapeutics | Oligomer-opioid agonist conjugates |
| US10512644B2 (en) | 2007-03-12 | 2019-12-24 | Inheris Pharmaceuticals, Inc. | Oligomer-opioid agonist conjugates |
| AU2008226791B2 (en) | 2007-03-12 | 2014-01-16 | Nektar Therapeutics | Oligomer-antihistamine conjugates |
| AU2008226822B2 (en) | 2007-03-12 | 2013-08-01 | Nektar Therapeutics | Oligomer-opioid agonist conjugates |
| US8389759B2 (en) | 2007-03-12 | 2013-03-05 | Nektar Therapeutics | Oligomer-anticholinergic agent conjugates |
| HRP20130382T1 (en) | 2007-04-03 | 2013-05-31 | Biogenerix Ag | TREATMENT PROCEDURES FOR HELP IN GLYCOPEGILATED G-CSF |
| US20080287633A1 (en) * | 2007-05-18 | 2008-11-20 | Drumheller Paul D | Hydrogel Materials |
| CN101679625B (en) * | 2007-05-29 | 2013-06-26 | 栗村化学株式会社 | Chain-end functionalized methoxypolyethylene glycol and its metal nanoparticles |
| CA2690611C (en) | 2007-06-12 | 2015-12-08 | Novo Nordisk A/S | Improved process for the production of nucleotide sugars |
| JP2008308690A (en) * | 2007-06-13 | 2008-12-25 | Bio-Cancer Treatment Internatl Ltd | POLY (ETHYLENE GLYCOL) FUNCTIONAL DERIVATIVE AND METHOD FOR PRODUCING THE SAME |
| WO2009002873A1 (en) * | 2007-06-22 | 2008-12-31 | Cvi Pharmaceuticals Limited | Compounds, compositions and methods for reducing lipid levels |
| US20090075887A1 (en) * | 2007-08-21 | 2009-03-19 | Genzyme Corporation | Treatment with Kallikrein Inhibitors |
| US8207112B2 (en) | 2007-08-29 | 2012-06-26 | Biogenerix Ag | Liquid formulation of G-CSF conjugate |
| WO2009032286A2 (en) | 2007-09-06 | 2009-03-12 | Nektar Therapeutics Al, Corporation | Oligomer-calcium channel blocker conjugates |
| WO2009042064A2 (en) | 2007-09-21 | 2009-04-02 | Nektar Therapeutics Al, Corporation | Oligomer-nucleoside phosphate conjugates |
| US20100280098A1 (en) * | 2007-10-05 | 2010-11-04 | Juliano Rudolph L | Receptor targeted oligonucleotides |
| US8796248B2 (en) * | 2007-10-05 | 2014-08-05 | Nektar Therapeutics | Oligomer-corticosteroid conjugates |
| WO2009048909A1 (en) * | 2007-10-08 | 2009-04-16 | Quintessence Biosciences, Inc. | Compositions and methods for ribonuclease-based therapies |
| WO2009054916A2 (en) * | 2007-10-19 | 2009-04-30 | Nektar Therapeutics Al, Corporation | Oligomer conjugates of lidocaine and its derivatives |
| US8440787B2 (en) * | 2007-10-23 | 2013-05-14 | Nektar Therapeutics | Hydroxyapatite-targeting multiarm polymers and conjugates made therefrom |
| US8853247B2 (en) | 2007-11-02 | 2014-10-07 | Nektar Therapeutics | Oligomer-nitroimidazole anti-infective conjugates |
| KR20100095441A (en) * | 2007-11-09 | 2010-08-30 | 백스터 인터내셔널 인코포레이티드 | Modified recombinant factor viii and von willebrand factor and methods of use |
| US20090123519A1 (en) * | 2007-11-12 | 2009-05-14 | Surmodics, Inc. | Swellable hydrogel matrix and methods |
| WO2009067175A2 (en) | 2007-11-16 | 2009-05-28 | Nektar Therapeutics Al, Corporation | Oligomer-dantrolene conjugates and related compounds |
| AU2008331868B2 (en) | 2007-11-28 | 2015-02-12 | Nektar Therapeutics | Oligomer-tricyclic conjugates |
| US20110009446A1 (en) * | 2008-01-11 | 2011-01-13 | Nektar Therapeutics | Oligomer-guanidine class conjugates |
| US8685979B2 (en) | 2008-01-25 | 2014-04-01 | Nektar Therapeutics | Oligomer-diarylpiperazine conjugates |
| EP2254601B1 (en) | 2008-02-08 | 2019-05-29 | Nektar Therapeutics | Oligomer-cannabinoid conjugates |
| US8466276B2 (en) * | 2008-02-22 | 2013-06-18 | Nektar Therapeutics | Oligomer conjugates of heteropentacyclic nucleosides |
| PL2257311T3 (en) | 2008-02-27 | 2014-09-30 | Novo Nordisk As | Conjugated factor viii molecules |
| TWI395593B (en) | 2008-03-06 | 2013-05-11 | Halozyme Inc | In vivo temporal control of activatable matrix-degrading enzymes |
| US20090226531A1 (en) * | 2008-03-07 | 2009-09-10 | Allergan, Inc. | Methods and composition for intraocular delivery of therapeutic sirna |
| US9006219B2 (en) * | 2008-03-12 | 2015-04-14 | Nektar Therapeutics | Oligomer-foscarnet conjugates |
| US9095620B2 (en) * | 2008-03-12 | 2015-08-04 | Nektar Therapeutics | Reagents |
| WO2009120358A1 (en) * | 2008-03-27 | 2009-10-01 | Nektar Therapeutics | Oligomer-nitrogenous base conjugates |
| US20110045510A1 (en) * | 2008-04-03 | 2011-02-24 | Kurt Lang | Pegylated insulin-like-growth-factor assay |
| JP5173018B2 (en) * | 2008-04-03 | 2013-03-27 | エフ.ホフマン−ラ ロシュ アーゲー | Use of pegylated IGF-I variants for the treatment of neuromuscular disorders |
| WO2009126333A1 (en) | 2008-04-11 | 2009-10-15 | Nektar Therapeutics | Oligomer-aryloxy-substituted propanamine conjugates |
| CA2721183C (en) | 2008-04-11 | 2019-07-16 | Alnylam Pharmaceuticals, Inc. | Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components |
| KR20130116386A (en) | 2008-04-14 | 2013-10-23 | 할로자임, 아이엔씨 | Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions |
| US9095621B2 (en) | 2008-04-25 | 2015-08-04 | Nektar Therapeutics | Oligome-bis-chromonyl compound conjugates |
| TWI394580B (en) | 2008-04-28 | 2013-05-01 | Halozyme Inc | Super fast-acting insulin compositions |
| WO2009151590A2 (en) * | 2008-06-09 | 2009-12-17 | Nektar Therapeutics | Methods of treating cyp2d6 alternative metabolizers |
| US8815818B2 (en) | 2008-07-18 | 2014-08-26 | Rxi Pharmaceuticals Corporation | Phagocytic cell delivery of RNAI |
| AU2009282413B2 (en) | 2008-08-11 | 2014-07-17 | Nektar Therapeutics | Multi-arm polymeric alkanoate conjugates |
| JP5827123B2 (en) * | 2008-09-16 | 2015-12-02 | ウェルズ ファーゴ バンク ナショナル アソシエイション | PEGylated opioids with low potential for abuse |
| WO2010033226A1 (en) * | 2008-09-17 | 2010-03-25 | Nektar Therapeutics | Oligomer-protease inhibitor conjugates |
| US20110195940A1 (en) | 2008-09-17 | 2011-08-11 | Nektar Therapeutics | Protease Inhibitors Having Enhanced Features |
| EP2340047A1 (en) * | 2008-09-19 | 2011-07-06 | Nektar Therapeutics | Polymer conjugates of kiss1 peptides |
| EP2344200A2 (en) * | 2008-09-19 | 2011-07-20 | Nektar Therapeutics | Modified therapeutics peptides, methods of their preparation and use |
| WO2010033240A2 (en) | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Carbohydrate-based drug delivery polymers and conjugates thereof |
| EP2334335A1 (en) * | 2008-09-19 | 2011-06-22 | Nektar Therapeutics | Polymer conjugates of cd-np peptides |
| US20110171164A1 (en) * | 2008-09-19 | 2011-07-14 | Nektar Therapeutics | Polymer conjugates of glp-2-like peptides |
| US20110171165A1 (en) * | 2008-09-19 | 2011-07-14 | Nektar Therapeutics | Polymer conjugates of opioid growth factor peptides |
| WO2010033204A2 (en) * | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Polymer conjugates of c-peptides |
| WO2010033227A1 (en) * | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Polymer conjugates of thymosin alpha 1 peptides |
| US20110171166A1 (en) * | 2008-09-19 | 2011-07-14 | Nektar Therapeutics | Polymer conjugates of osteocalcin peptides |
| US20110165113A1 (en) * | 2008-09-19 | 2011-07-07 | Nektar Therapeutics | Polymer conjugates of v681-like peptides |
| WO2010033222A2 (en) * | 2008-09-19 | 2010-03-25 | Netkar Therapeutics | Polymer conjugates of ziconotide peptides |
| WO2010033221A1 (en) | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Polymer conjugates of protegrin peptides |
| US20110237524A1 (en) * | 2008-09-19 | 2011-09-29 | Nektar Therapeutics | Polymer conjugates of aod-like peptides |
| EP2342340A1 (en) | 2008-09-22 | 2011-07-13 | Rxi Pharmaceuticals Corporation | Rna interference in skin indications |
| AU2009298802A1 (en) | 2008-09-23 | 2010-04-08 | Alnylam Pharmaceuticals, Inc. | Chemical modifications of monomers and oligonucleotides with cycloaddition |
| BRPI0920743A2 (en) | 2008-10-01 | 2016-09-20 | Quintessence Biosciences Inc | therapeutic ribonucleases |
| CN111808084A (en) | 2008-11-10 | 2020-10-23 | 阿布特斯生物制药公司 | Novel lipids and compositions for delivery of therapeutic agents |
| EA022752B1 (en) | 2008-12-09 | 2016-02-29 | Галозим, Инк. | LONG SOLUBLE PH2020 POLYPEPTIDES AND THEIR USE |
| WO2010078536A1 (en) | 2009-01-05 | 2010-07-08 | Rxi Pharmaceuticals Corporation | Inhibition of pcsk9 through rnai |
| US8637454B2 (en) * | 2009-01-06 | 2014-01-28 | Dyax Corp. | Treatment of mucositis with kallikrein inhibitors |
| MX2011007940A (en) | 2009-01-28 | 2011-08-15 | Nektar Therapeutics | Oligomer-phenothiazine conjugates. |
| US9192681B2 (en) | 2009-02-24 | 2015-11-24 | Nektar Therapeutics | Oligomer-amino acid conjugates |
| AU2010221419B2 (en) | 2009-03-02 | 2015-10-01 | Alnylam Pharmaceuticals, Inc. | Nucleic acid chemical modifications |
| US9688631B2 (en) * | 2009-03-02 | 2017-06-27 | Isp Investments Llc | Thermosetting ring-opening metathesis polymerization materials with thermally degradable linkages |
| US8765171B2 (en) * | 2009-03-09 | 2014-07-01 | The Regents Of The University Of California | Methods and compositions for liposomal formulation of antigens and uses thereof |
| WO2010120388A1 (en) | 2009-04-17 | 2010-10-21 | Nektar Therapeutics | Oligomer-protein tyrosine kinase inhibitor conjugates |
| US8530492B2 (en) | 2009-04-17 | 2013-09-10 | Nektar Therapeutics | Oligomer-protein tyrosine kinase inhibitor conjugates |
| CN101870767B (en) * | 2009-04-24 | 2012-09-12 | 石药集团中奇制药技术(石家庄)有限公司 | Preparation method of pegylated 1,2-bialiphatic acyl phosphatidylethanolamine |
| CA2977830C (en) * | 2009-05-04 | 2019-09-17 | Incept, Llc | Biomaterials for track and puncture closure |
| US8785661B2 (en) | 2009-05-13 | 2014-07-22 | Nektar Therapeutics | Oligome-containing pyrrolidine compounds |
| JP5656980B2 (en) | 2009-05-13 | 2015-01-21 | ウェルズ ファーゴ バンク ナショナル アソシエイション | Substituted aromatic triazine compounds containing oligomers |
| NO2440239T3 (en) | 2009-06-09 | 2018-02-10 | ||
| KR101766408B1 (en) | 2009-06-10 | 2017-08-10 | 알닐람 파마슈티칼스 인코포레이티드 | Improved lipid formulation |
| JP2012530069A (en) | 2009-06-12 | 2012-11-29 | ネクター セラピューティックス | Covalent conjugate comprising a protease inhibitor, a water-soluble non-peptide oligomer and a lipophilic moiety |
| US9290577B2 (en) | 2009-07-03 | 2016-03-22 | Avipep Pty Limited | Immuno-conjugates and methods for producing them |
| WO2011003633A1 (en) | 2009-07-06 | 2011-01-13 | Alize Pharma Ii | Pegylated l-asparaginase |
| RS57077B2 (en) * | 2009-07-06 | 2023-06-30 | Jazz Pharmaceuticals Ii Sas | PEGYLATED L-ASPARAGINASE |
| US20110009628A1 (en) * | 2009-07-08 | 2011-01-13 | Haiyan Liu | Compounds and Compositions for Modulating Lipid Levels and Methods of Preparing Same |
| MX2012000980A (en) | 2009-07-21 | 2012-06-12 | Nektar Therapeutics | Oligomer-opioid agonist conjugates. |
| CN102612362A (en) | 2009-08-05 | 2012-07-25 | 皮里斯股份公司 | Controlled release formulations of lipocalin muteins |
| HUE028832T2 (en) | 2009-09-17 | 2017-01-30 | Baxalta Inc | Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof |
| WO2011035065A1 (en) | 2009-09-17 | 2011-03-24 | Nektar Therapeutics | Monoconjugated chitosans as delivery agents for small interfering nucleic acids |
| AU2010315805B2 (en) | 2009-09-29 | 2015-09-17 | Nektar Therapeutics | Oligomer-calcimimetic conjugates and related compounds |
| US8722732B2 (en) | 2009-09-29 | 2014-05-13 | Nektar Therapeutics | Oligomer-calcimimetic conjugates and related compounds |
| EP2494073B1 (en) | 2009-10-26 | 2017-11-29 | AGCT GmbH | Nucleotide conjugates and methods of uses thereof |
| EP3296398A1 (en) | 2009-12-07 | 2018-03-21 | Arbutus Biopharma Corporation | Compositions for nucleic acid delivery |
| EP3494963A1 (en) | 2009-12-18 | 2019-06-12 | The University of British Columbia | Methods and compositions for delivery of nucleic acids |
| US20110152188A1 (en) * | 2009-12-23 | 2011-06-23 | Hanns-Christian Mahler | Pharmaceutical compositions of igf/i proteins |
| JP2013514788A (en) | 2009-12-23 | 2013-05-02 | アビペップ ピーティーワイ リミテッド | Immunoconjugate and production method 2 |
| SMT201800552T1 (en) | 2010-01-06 | 2018-11-09 | Dyax Corp | Plasma kallikrein binding proteins |
| US20130023553A1 (en) | 2010-01-12 | 2013-01-24 | Nektar Therapeutics | Pegylated opioids with low potential for abuse and side effects |
| WO2011091050A1 (en) | 2010-01-19 | 2011-07-28 | Nektar Therapeutics | Oligomer-tricyclic conjugates |
| US9198972B2 (en) | 2010-01-28 | 2015-12-01 | Alnylam Pharmaceuticals, Inc. | Monomers and oligonucleotides comprising cycloaddition adduct(s) |
| WO2011094580A2 (en) | 2010-01-28 | 2011-08-04 | Alnylam Pharmaceuticals, Inc. | Chelated copper for use in the preparation of conjugated oligonucleotides |
| WO2011103559A1 (en) | 2010-02-22 | 2011-08-25 | Nektar Therapeutics | Oligomer modified diaromatic substituted compounds |
| US20110224383A1 (en) * | 2010-03-11 | 2011-09-15 | Intezyne Technologies, Inc. | Poly(ethylene glycol) derivatives for metal-free click chemistry |
| US9102938B2 (en) | 2010-04-01 | 2015-08-11 | Alnylam Pharmaceuticals, Inc. | 2′ and 5′ modified monomers and oligonucleotides |
| WO2011133868A2 (en) | 2010-04-22 | 2011-10-27 | Alnylam Pharmaceuticals, Inc. | Conformationally restricted dinucleotide monomers and oligonucleotides |
| US10913767B2 (en) | 2010-04-22 | 2021-02-09 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides comprising acyclic and abasic nucleosides and analogs |
| WO2011133871A2 (en) | 2010-04-22 | 2011-10-27 | Alnylam Pharmaceuticals, Inc. | 5'-end derivatives |
| KR20130115086A (en) | 2010-05-17 | 2013-10-21 | 세빅스 인코포레이티드 | Pegylated c-peptide |
| US20130236968A1 (en) | 2010-06-21 | 2013-09-12 | Alnylam Pharmaceuticals, Inc. | Multifunctional copolymers for nucleic acid delivery |
| WO2012012300A2 (en) | 2010-07-20 | 2012-01-26 | Halozyme, Inc. | Adverse side-effects associated with administration of an anti-hyaluronan agent and methods for ameliorating or preventing the side-effects |
| WO2012016188A2 (en) | 2010-07-30 | 2012-02-02 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for delivery of active agents |
| WO2012016184A2 (en) | 2010-07-30 | 2012-02-02 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for delivery of active agents |
| WO2012020124A1 (en) | 2010-08-12 | 2012-02-16 | Ac Immune S.A. | Vaccine engineering |
| WO2012044992A2 (en) | 2010-09-30 | 2012-04-05 | Agency For Science, Technology And Research (A*Star) | Methods and reagents for detection and treatment of esophageal metaplasia |
| WO2012051551A1 (en) | 2010-10-15 | 2012-04-19 | Nektar Therapeutics | N-optionally substituted aryl-2-oligomer-3-alkoxypropionamides |
| WO2012054822A1 (en) | 2010-10-22 | 2012-04-26 | Nektar Therapeutics | Pharmacologically active polymer-glp-1 conjugates |
| JP6027011B2 (en) | 2010-10-26 | 2016-11-16 | エーシー イミューン ソシエテ アノニム | Liposome-based constructs containing peptides modified by hydrophobic moieties |
| TWI557135B (en) | 2010-11-03 | 2016-11-11 | 介控生化科技公司 | Modified ninth factor multi-peptide and use thereof |
| JP6002144B2 (en) | 2010-12-10 | 2016-10-05 | ネクター セラピューティクス | Hydroxylated tricyclic compounds |
| WO2012082995A1 (en) | 2010-12-15 | 2012-06-21 | Nektar Therapeutics | Oligomer-containing hydantoin compounds |
| WO2012083153A1 (en) | 2010-12-16 | 2012-06-21 | Nektar Therapeutics | Oligomer-containing apremilast moiety compounds |
| US20140371258A1 (en) | 2010-12-17 | 2014-12-18 | Nektar Therapeutics | Water-Soluble Polymer Conjugates of Topotecan |
| EP2654795B1 (en) | 2010-12-21 | 2018-03-07 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of pemetrexed-based compounds |
| WO2012088422A1 (en) | 2010-12-22 | 2012-06-28 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of taxane-based compounds |
| WO2012088445A1 (en) | 2010-12-22 | 2012-06-28 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds |
| KR102320178B1 (en) | 2011-01-06 | 2021-11-02 | 다케다 파머수티컬 컴패니 리미티드 | Plasma kallikrein binding proteins |
| CA2824526C (en) | 2011-01-11 | 2020-07-07 | Alnylam Pharmaceuticals, Inc. | Pegylated lipids and their use for drug delivery |
| WO2012109387A1 (en) | 2011-02-08 | 2012-08-16 | Halozyme, Inc. | Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia |
| US9944688B2 (en) * | 2011-06-02 | 2018-04-17 | Hanmi Science Co., Ltd. | Non-peptidyl polymer-insulin multimer and method for producing the same |
| US20130011378A1 (en) | 2011-06-17 | 2013-01-10 | Tzung-Horng Yang | Stable formulations of a hyaluronan-degrading enzyme |
| CA2839512C (en) | 2011-06-17 | 2018-01-02 | Halozyme, Inc. | Continuous subcutaneous insulin infusion methods with a hyaluronan-degrading enzyme |
| NZ618331A (en) | 2011-06-17 | 2016-04-29 | Halozyme Inc | Stable formulations of a hyaluronan-degrading enzyme |
| WO2013040501A1 (en) | 2011-09-16 | 2013-03-21 | Pharmathene, Inc. | Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and uses thereof |
| EP3456317B1 (en) | 2011-09-27 | 2025-09-24 | Alnylam Pharmaceuticals, Inc. | Di-aliphatic substituted pegylated lipids |
| JP6162707B2 (en) | 2011-10-24 | 2017-07-12 | ハロザイム インコーポレイテッド | Companion diagnostics for antihyaluronan treatment and methods of use thereof |
| US10525054B2 (en) | 2011-11-07 | 2020-01-07 | Inheris Biopharma, Inc. | Compositions, dosage forms, and co-administration of an opioid agonist compound and an analgesic compound |
| MX348933B (en) | 2011-11-07 | 2017-07-03 | Nektar Therapeutics | Compositions, dosage forms, and coadministration of an opioid agonist compound and an analgesic compound. |
| US8962553B2 (en) | 2011-11-17 | 2015-02-24 | Cebix Ab | Method of treating a diabetic subject having a microvascular impairment disorder by a pegylated C-peptide |
| FR2984328B1 (en) | 2011-12-20 | 2016-12-30 | Bio-Rad Innovations | METHOD FOR DETECTING HEPATITIS C VIRUS INFECTION |
| WO2013102144A2 (en) | 2011-12-30 | 2013-07-04 | Halozyme, Inc. | Ph20 polypeptede variants, formulations and uses thereof |
| PL2831237T3 (en) | 2012-03-30 | 2018-06-29 | The Board Of Regents Of The University Of Oklahoma | High molecular weight heparosan polymers and methods of production and use thereof |
| US8956682B2 (en) | 2012-04-02 | 2015-02-17 | Surmodics, Inc. | Hydrophilic polymeric coatings for medical articles with visualization moiety |
| CN108686203A (en) | 2012-04-04 | 2018-10-23 | 哈洛齐梅公司 | Use the combination treatment of anti-hyaluronic acid agent and cancer target taxane |
| EP2833883A4 (en) | 2012-04-06 | 2015-12-23 | Indus Pharmaceuticals Inc | Novel compositions of combinations of non-covalent dna binding agents and anti-cancer and/or anti-inflammatory agents and their use in disease treatment |
| US9375486B2 (en) | 2012-09-17 | 2016-06-28 | Nektar Therapeutics | Oligomer-containing benzamide-based compounds |
| WO2014062856A1 (en) | 2012-10-16 | 2014-04-24 | Halozyme, Inc. | Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods |
| CN104837996A (en) | 2012-11-15 | 2015-08-12 | 罗氏创新中心哥本哈根有限公司 | Anti APOB antisense conjugate compounds |
| WO2014093869A1 (en) | 2012-12-13 | 2014-06-19 | University Of Kansas | 6-substituted quinazolinone inhibitors |
| CN105916860A (en) | 2013-03-14 | 2016-08-31 | 美艾利尔圣地亚哥公司 | Synthesis and method of use of 6-monoacetylmorphine analogs |
| PE20151747A1 (en) | 2013-03-14 | 2015-12-18 | Univ Massachusetts | METHOD TO INHIBIT CATARACTS AND PRESBYCIA |
| US9937231B2 (en) | 2013-03-27 | 2018-04-10 | The General Hospital Corporation | Methods and agents for treating Alzheimer's disease |
| TW201534726A (en) | 2013-07-03 | 2015-09-16 | Halozyme Inc | Thermally stable PH20 hyaluronidase variants and uses thereof |
| WO2015027160A2 (en) | 2013-08-22 | 2015-02-26 | Northeastern University | Allosteric modulators of the cannibinoid 1 receptor |
| NZ758049A (en) | 2013-10-15 | 2024-03-22 | Seagen Inc | Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics |
| EP3078699B1 (en) | 2013-12-02 | 2019-08-21 | Jenkem Technology Co. Ltd. (Tianjin) | Multi-arm polyethylene glycol-nitrine derivative |
| CN104774161B (en) * | 2014-01-13 | 2017-08-25 | 成都福瑞康生物科技有限公司 | Polypeptide, protein PEG dressing agent synthetic methods |
| US10428158B2 (en) | 2014-03-27 | 2019-10-01 | Dyax Corp. | Compositions and methods for treatment of diabetic macular edema |
| WO2015175774A1 (en) | 2014-05-14 | 2015-11-19 | Trustees Of Dartmouth College | Deimmunized lysostaphin and methods of use |
| US9611270B2 (en) | 2014-08-01 | 2017-04-04 | University Of Kansas | Inhibitors of CYP17A1 |
| PT3186281T (en) | 2014-08-28 | 2019-07-10 | Halozyme Inc | Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor |
| BR112017007765B1 (en) | 2014-10-14 | 2023-10-03 | Halozyme, Inc | COMPOSITIONS OF ADENOSINE DEAMINASE-2 (ADA2), VARIANTS THEREOF AND METHODS OF USING THE SAME |
| US10118896B2 (en) | 2014-11-26 | 2018-11-06 | University Of Kansas | Antagonists of the kappa opioid receptor |
| JP2018504380A (en) | 2014-12-18 | 2018-02-15 | アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. | REVERSIR ™ compounds |
| JP6638970B2 (en) | 2015-06-30 | 2020-02-05 | 株式会社 東北テクノアーチ | Method for producing hetero-type monodisperse polyethylene glycol and intermediate for producing hetero-type monodisperse polyethylene glycol |
| CA3205381A1 (en) | 2015-07-17 | 2017-01-26 | Alnylam Pharmaceuticals, Inc. | Multi-targeted single entity conjugates |
| MX376641B (en) | 2015-11-13 | 2025-03-07 | Univ Massachusetts | Bifunctional molecules containing peg for use in inhibiting cataracts and presbyopia |
| US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
| KR20180090290A (en) | 2015-12-04 | 2018-08-10 | 시애틀 지네틱스, 인크. | Conjugates of Quaternized Tubular Compounds |
| EP3387018A1 (en) | 2015-12-11 | 2018-10-17 | Dyax Corp. | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
| CN109843919A (en) | 2016-03-25 | 2019-06-04 | 西雅图基因公司 | The method for being used to prepare the agent-linker and its intermediate of Pegylation |
| CN107375288B (en) | 2016-05-16 | 2019-08-23 | 博瑞生物医药(苏州)股份有限公司 | The polymerization target anticancer conjugate of multi-arm |
| CA3024622A1 (en) | 2016-05-18 | 2017-11-23 | Alere San Diego, Inc. | 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine analogs and methods for their synthesis and use |
| CN109843339B (en) | 2016-06-23 | 2023-07-07 | 康奈尔大学 | Dual targeting constructs affecting tumor killing |
| CN109843338B (en) | 2016-06-28 | 2022-12-13 | 康奈尔大学 | Containing PSMA inhibitors 18 F-labelled triazoles |
| CN107973790A (en) | 2016-10-22 | 2018-05-01 | 合帕吉恩治疗公司 | Heterocyclic FXR conditioning agent |
| EP3535386A4 (en) | 2016-11-04 | 2020-04-15 | Georgia State University Research Foundation, Inc. | ENDOTOXIN-FREE ASPARAGINASE |
| CN108017636A (en) | 2016-11-04 | 2018-05-11 | 合帕吉恩治疗公司 | Nitrogen-containing heterocycle compound as FXR conditioning agents |
| JP7244987B2 (en) | 2016-12-14 | 2023-03-23 | シージェン インコーポレイテッド | Multidrug Antibody Drug Conjugates |
| US10800817B2 (en) | 2016-12-19 | 2020-10-13 | Morehouse School Of Medicine | Compositions and methods for treating diseases by inhibiting exosome release |
| WO2018118015A1 (en) | 2016-12-19 | 2018-06-28 | Morehouse School Of Medicine | Compositions and methods for treating diseases by inhibiting exosome release |
| KR102648564B1 (en) | 2017-03-24 | 2024-03-19 | 씨젠 인크. | Manufacturing process of glucuronide drug-linker and its intermediates |
| US12544344B2 (en) | 2017-04-19 | 2026-02-10 | Phio Pharmaceuticals Corp. | Topical delivery of nucleic acid compounds |
| AU2018283973B2 (en) | 2017-06-11 | 2025-04-24 | Molecular Express, Inc. | Methods and compositions for substance use disorder vaccine formulations and uses thereof |
| CA3177086A1 (en) | 2017-06-22 | 2018-12-27 | Catalyst Biosciences, Inc. | Modified membrane type serine protease 1 (mtsp-1) polypeptides and methods of use |
| US11491212B1 (en) | 2017-09-27 | 2022-11-08 | Catalyst Biosciences, Inc. | Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B |
| CA3085600A1 (en) | 2017-12-22 | 2019-06-27 | Cornell University | 18f-labeled peptide ligands useful in pet and cerenkov luminescene imaging |
| MX2020011570A (en) | 2018-05-07 | 2020-11-24 | Alnylam Pharmaceuticals Inc | Extrahepatic delivery. |
| US20190351031A1 (en) | 2018-05-16 | 2019-11-21 | Halozyme, Inc. | Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20 |
| TWI851577B (en) | 2018-06-07 | 2024-08-11 | 美商思進公司 | Camptothecin conjugates |
| WO2020069055A1 (en) | 2018-09-28 | 2020-04-02 | Alnylam Pharmaceuticals, Inc. | Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases |
| CA3123872A1 (en) | 2018-12-28 | 2020-07-02 | Catalyst Biosciences, Inc. | Modified urokinase-type plasminogen activator polypeptides and methods of use |
| US11613744B2 (en) | 2018-12-28 | 2023-03-28 | Vertex Pharmaceuticals Incorporated | Modified urokinase-type plasminogen activator polypeptides and methods of use |
| AU2020279101B2 (en) | 2019-05-17 | 2025-07-24 | Alnylam Pharmaceuticals, Inc. | Oral delivery of oligonucleotides |
| CN114929284A (en) | 2019-10-04 | 2022-08-19 | 西根公司 | Camptothecin peptide conjugates |
| BR112022007795A2 (en) | 2019-11-06 | 2022-07-05 | Alnylam Pharmaceuticals Inc | EXTRAHEPATIC ADMINISTRATION |
| WO2021092145A1 (en) | 2019-11-06 | 2021-05-14 | Alnylam Pharmaceuticals, Inc. | Transthyretin (ttr) irna composition and methods of use thereof for treating or preventing ttr-associated ocular diseases |
| EP4090427A1 (en) | 2020-01-13 | 2022-11-23 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack |
| WO2021154414A2 (en) | 2020-01-29 | 2021-08-05 | Catalyst Biosciences, Inc. | Gene therapy for hemophilia b with a chimeric aav capsid vector encoding modified factor ix polypeptides |
| GB2613225B (en) | 2020-03-04 | 2024-01-03 | Verve Therapeutics Inc | Compositions and methods for targeted RNA delivery |
| AU2021251875A1 (en) | 2020-04-10 | 2022-11-03 | Seagen Inc. | Charge variant linkers |
| EP4143227A2 (en) | 2020-04-30 | 2023-03-08 | Sairopa B.V. | Anti-cd103 antibodies |
| WO2022011214A1 (en) | 2020-07-10 | 2022-01-13 | Alnylam Pharmaceuticals, Inc. | Circular sirnas |
| EP4208549A4 (en) | 2020-09-04 | 2025-04-16 | Verve Therapeutics, Inc. | Compositions and methods for capping rnas |
| EP4271696A2 (en) | 2020-12-31 | 2023-11-08 | Alnylam Pharmaceuticals, Inc. | Cyclic-disulfide modified phosphate based oligonucleotide prodrugs |
| EP4271695A2 (en) | 2020-12-31 | 2023-11-08 | Alnylam Pharmaceuticals, Inc. | 2'-modified nucleoside based oligonucleotide prodrugs |
| JP2024503508A (en) | 2021-01-15 | 2024-01-25 | シージェン インコーポレイテッド | Immunomodulatory antibody-drug conjugates |
| US12024515B2 (en) | 2021-01-22 | 2024-07-02 | University Of Kansas | Kifunensine derivatives |
| BR112023015561A2 (en) | 2021-02-03 | 2023-11-14 | Univ Minnesota | IMMUNOSTIMULATING AND CONJUGATED COMPOUNDS |
| BR112023018676A2 (en) | 2021-03-18 | 2023-10-10 | Seagen Inc | ANTIBODY-DRUG CONJUGATE, PHARMACEUTICAL COMPOSITION, METHODS OF TREATMENT OF A DISEASE OR CONDITION AND A CANCER, AND, LINDER-DRUG CONJUGATE COMPOSITION |
| WO2022211829A1 (en) | 2021-03-30 | 2022-10-06 | Jazz Pharmaceuticals Ireland Ltd. | Dosing of recombinant l-asparaginase |
| AU2022283467A1 (en) | 2021-05-28 | 2023-12-07 | Seagen Inc. | Anthracycline antibody conjugates |
| US11180534B1 (en) | 2021-06-04 | 2021-11-23 | Morehouse School Of Medicine | Compositions and methods for treating SARS-CoV-2 infections |
| WO2023283403A2 (en) | 2021-07-09 | 2023-01-12 | Alnylam Pharmaceuticals, Inc. | Bis-rnai compounds for cns delivery |
| MX2024000981A (en) | 2021-07-21 | 2024-02-12 | Alnylam Pharmaceuticals Inc | Metabolic disorder-associated target gene irna compositions and methods of use thereof. |
| WO2023015223A2 (en) | 2021-08-03 | 2023-02-09 | Verve Therapeutics, Inc. | Compositions and methods for targeted rna delivery |
| CN118369427A (en) | 2021-10-15 | 2024-07-19 | 阿尔尼拉姆医药品有限公司 | Extrahepatic delivery of IRNA compositions and methods of use thereof |
| ES3001145T1 (en) | 2021-11-09 | 2025-03-04 | Tubulis Gmbh | CONJUGATES COMPRISING A PHOSPHORUS (V) AND A CAMPTOTHECIN MOILARITY |
| WO2023083900A1 (en) | 2021-11-09 | 2023-05-19 | Tubulis Gmbh | Conjugates comprising a phosphorus (v) and a drug moiety |
| WO2023178289A2 (en) | 2022-03-17 | 2023-09-21 | Seagen Inc. | Camptothecin conjugates |
| EP4508051A1 (en) | 2022-04-12 | 2025-02-19 | Galderma Holding SA | Salts for mtor compounds |
| EP4518905A1 (en) | 2022-05-06 | 2025-03-12 | Seagen Inc. | Immunomodulatory antibody-drug conjugates |
| EP4522742A2 (en) | 2022-05-13 | 2025-03-19 | Alnylam Pharmaceuticals, Inc. | Single-stranded loop oligonucleotides |
| JP2025522880A (en) | 2022-06-30 | 2025-07-17 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | Cyclic disulfide-modified phosphate-based oligonucleotide prodrugs |
| US20260007728A1 (en) | 2022-07-14 | 2026-01-08 | Jazz Pharmaceuticals Ireland Ltd. | Combination therapies involving l-asparaginase |
| JP2025525904A (en) | 2022-08-03 | 2025-08-07 | シージェン インコーポレイテッド | Immunostimulatory anti-PD-L1-drug conjugates |
| EP4321522A1 (en) | 2022-08-12 | 2024-02-14 | Seagen Inc. | Cytotoxic compounds and conjugates thereof |
| WO2024073732A1 (en) | 2022-09-30 | 2024-04-04 | Alnylam Pharmaceuticals, Inc. | Modified double-stranded rna agents |
| PE20251849A1 (en) | 2022-10-18 | 2025-07-22 | Tubulis Gmbh | NOVEL ANTI-TPBG ANTIBODIES AND ANTIBODY-DRUG CONJUGATES BASED ON THE SAME, THERAPEUTIC METHODS AND USES THEREOF |
| JP2025536308A (en) | 2022-10-18 | 2025-11-05 | テューブリス ゲーエムベーハー | Novel antibody-drug conjugates with novel NaPi2b antibodies, therapeutic methods, and uses thereof - Patent Application 20070122999 |
| EP4619045A1 (en) | 2022-11-17 | 2025-09-24 | Sanofi | Ceacam5 antibody-drug conjugates and methods of use thereof |
| WO2024115353A1 (en) | 2022-11-28 | 2024-06-06 | Eth Zurich | Analytical composition for monitoring disinfection |
| WO2024129756A1 (en) | 2022-12-13 | 2024-06-20 | Seagen Inc. | Site-specific engineered cysteine antibody drug conjugates |
| EP4637832A1 (en) | 2022-12-22 | 2025-10-29 | Tubulis GmbH | Conjugates comprising a phosphorus(v) moiety and a drug |
| TW202449152A (en) | 2023-02-09 | 2024-12-16 | 美商艾拉倫製藥股份有限公司 | Reversir molecules and methods of use thereof |
| KR20260009305A (en) | 2023-04-12 | 2026-01-19 | 알닐람 파마슈티칼스 인코포레이티드 | Extrahepatic delivery of double-stranded RNA preparations |
| WO2024220889A1 (en) | 2023-04-20 | 2024-10-24 | Seagen Inc. | Sting agonist compounds and conjugates thereof |
| EP4709855A2 (en) | 2023-05-12 | 2026-03-18 | Alnylam Pharmaceuticals, Inc. | Single-stranded loop oligonucleotides |
| EP4731613A1 (en) | 2023-06-21 | 2026-04-29 | Valo Health, Inc. | Spirocyclic parp inhibitors and methods of use |
| EP4731631A1 (en) | 2023-06-21 | 2026-04-29 | Valo Health, Inc. | Benzamidazole diazapinone parp inhibitors and methods of use |
| WO2024261709A1 (en) | 2023-06-21 | 2024-12-26 | Valo Health, Inc. | Isoindolinone-containing parp inhibitors and methods of use |
| EP4731630A1 (en) | 2023-06-21 | 2026-04-29 | Valo Health, Inc. | Homophthalazinone indole parp inhibitors and methods of use |
| AU2024332412A1 (en) | 2023-09-01 | 2026-03-12 | Tubulis Gmbh | Methods of preparing phosphonamidate compounds |
| WO2025064660A2 (en) | 2023-09-21 | 2025-03-27 | Alnylam Pharmaceuticals, Inc. | Activin a receptor type 1c (acvr1c) irna compositions and methods of use thereof |
| AR134171A1 (en) | 2023-10-24 | 2025-12-10 | Seagen Inc | CHEMOTHERAPEUTIC COMPOUNDS AND METHODS OF USE |
| WO2025149947A1 (en) | 2024-01-12 | 2025-07-17 | Seagen Inc. | Antibody-drug conjugates |
| WO2025227129A2 (en) | 2024-04-25 | 2025-10-30 | Starrock Pharma Llc | Delivery vehicles comprising proglucagon derived polypeptides and anabolic polypeptides and uses thereof |
| US20250341516A1 (en) | 2024-05-01 | 2025-11-06 | BioLegend, Inc. | Compositions for use with multiple fluorophores and methods of using |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0067029A2 (en) * | 1981-06-10 | 1982-12-15 | Ajinomoto Co., Inc. | Oxygen carrier |
| US5328955A (en) * | 1988-11-21 | 1994-07-12 | Collagen Corporation | Collagen-polymer conjugates |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2631656C2 (en) * | 1976-07-14 | 1983-02-10 | Boehringer Mannheim Gmbh, 6800 Mannheim | Use of a hydroxysuccinimido ester derivative for binding biologically active proteins to one another and / or to liquid or solid carriers |
| EP0206448B1 (en) * | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4943626A (en) * | 1988-07-29 | 1990-07-24 | The Dow Chemical Company | Primary polyether active hydrogen compounds which are prepared from linked, protectively initiated polyalkyleneoxides |
| US5157075A (en) * | 1990-05-02 | 1992-10-20 | Taenaka Mining Co., Ltd. | Modified melanin |
| AU657483B2 (en) * | 1990-07-20 | 1995-03-16 | Pharmacia Ab | Heterobifunctional reagents and conjugates with oxaalkylene units for amphiphilic bridge structures |
| US5483008A (en) * | 1992-02-07 | 1996-01-09 | Research Development Corporation Of Japan | Polyether having heterofunctional groups at both ends, process for the preparation thereof and polymerization initiator therefor |
| IT1256420B (en) * | 1992-11-17 | 1995-12-05 | Elisabetta Ranucci | MONOFUNCTIONAL LOW N-ACRYLOYLMORPHOLINE POLYMERS EXTREMELY CONJUGATED WITH THE ENZYMES AND DRUGS |
| US5256819A (en) * | 1992-12-24 | 1993-10-26 | Shell Oil Company | Preparation of polyoxyalkylene-alpha,omega-dicarboxylic acids |
| US5446090A (en) * | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
-
1995
- 1995-10-02 US US08/642,231 patent/US5672662A/en not_active Expired - Lifetime
-
1996
- 1996-07-03 AU AU63457/96A patent/AU6345796A/en not_active Abandoned
- 1996-07-03 WO PCT/US1996/011261 patent/WO1997003106A1/en not_active Ceased
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0067029A2 (en) * | 1981-06-10 | 1982-12-15 | Ajinomoto Co., Inc. | Oxygen carrier |
| US5328955A (en) * | 1988-11-21 | 1994-07-12 | Collagen Corporation | Collagen-polymer conjugates |
Non-Patent Citations (2)
| Title |
|---|
| SAMUEL ZALIPSKY ET AL: "Succinimidyl Carbonates of Polyethylene Glycol: Useful Reactive Polymers for Preparation of Protein Conjugates", POLYMER PREPRINTS, vol. 31, no. 2, 1990 * |
| SAMUEL ZALIPSKY: "Synthesis of an End-Group Functionalized Polyethylene Glycol-Lipid Conjugate for Preparation of Polymer-Grafted Liposomes", BIOCONJUGATE CHEM., vol. 4, 1993 * |
Cited By (215)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6448369B1 (en) | 1997-11-06 | 2002-09-10 | Shearwater Corporation | Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation |
| US7642323B2 (en) | 1997-11-06 | 2010-01-05 | Nektar Therapeutics | Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation |
| US8940801B2 (en) | 1997-11-06 | 2015-01-27 | Nektar Therapeutics | Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation |
| US10035880B2 (en) | 1997-11-06 | 2018-07-31 | Nektar Therapeutics | Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation |
| US6864327B2 (en) | 1997-11-06 | 2005-03-08 | Nektar Therapeutics Al, Corporation | Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation |
| US7223803B2 (en) | 1998-03-12 | 2007-05-29 | Nektar Therapeutics Al, Corporation | Polyethylene (glycol) derivatives with proximal reactive groups |
| EP1411075A3 (en) * | 1998-03-12 | 2004-07-28 | Nektar Therapeutics Al, Corporation | Method for preparing polymer conjugates |
| US7528202B2 (en) | 1998-03-12 | 2009-05-05 | Nektar Therapeutics Al, Corporation | Poly (ethylene glycol) derivatives with proximal reactive groups |
| US6541543B2 (en) | 1998-03-12 | 2003-04-01 | Shearwater Corporation | Poly (ethylene glycol) derivatives with proximal reactive groups |
| US8003742B2 (en) | 1998-03-12 | 2011-08-23 | Nektar Therapeutics | Polymer derivatives with proximal reactive groups |
| US6664331B2 (en) | 1998-03-12 | 2003-12-16 | Nektar Therapeutics Al, Corporation | Poly(ethylene glycol) derivatives with proximal reactive groups |
| WO1999045964A1 (en) * | 1998-03-12 | 1999-09-16 | Shearwater Polymers, Incorporated | Poly(ethylene glycol) derivatives with proximal reactive groups |
| US7714088B2 (en) | 1998-03-12 | 2010-05-11 | Nektar Therapeutics | Poly(ethylene glycol) derivatives with proximal reactive groups |
| US7030278B2 (en) | 1998-03-12 | 2006-04-18 | Nektar Therapeutics Al, Corporation | Polyethylene(Glycol) derivatives with proximal reactive groups |
| US6437025B1 (en) | 1998-03-12 | 2002-08-20 | Shearwater Corporation | Poly(ethylene glycol) derivatives with proximal reactive groups |
| WO2001026692A1 (en) * | 1999-10-08 | 2001-04-19 | Shearwater Corporation | Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation |
| US7674879B2 (en) | 1999-12-22 | 2010-03-09 | Nektar Therapeutics | Sterically hindered poly(ethylene glycol) alkanoic acids and derivatives thereof |
| US7205380B2 (en) | 1999-12-22 | 2007-04-17 | Nektar Therapeutics Al, Corporation | Sterically hindered poly (ethylene glycol) alkanoic acids and derivatives thereof |
| US8183338B2 (en) | 1999-12-22 | 2012-05-22 | Nektar Therapeutics | Sterically hindered poly(ethylene glycol) alkanoic acids and derivatives thereof |
| AU781839B2 (en) * | 1999-12-22 | 2005-06-16 | Nektar Therapeutics | Sterically hindered derivatives of water soluble polymers |
| US7405266B2 (en) | 1999-12-22 | 2008-07-29 | Nektar Therapeutics Al, Corporation | Sterically hindered poly(ethylene glycol) alkanoic acids and derivatives thereof |
| US6495659B2 (en) | 1999-12-22 | 2002-12-17 | Shearwater Corporation | Sterically hindered poly(ethylene glycol) alkanoic acids and derivatives thereof |
| US6992168B2 (en) | 1999-12-22 | 2006-01-31 | Nektar Therapeutics Al, Corporation | Sterically hindered poly(ethylene glycol) alkanoic acids and derivatives thereof |
| US6737505B2 (en) | 1999-12-22 | 2004-05-18 | Nektar Therapeutics Al, Corporation | Sterically hindered poly(ethylene glycol) alkanoic acids and derivatives thereof |
| WO2001046291A1 (en) * | 1999-12-22 | 2001-06-28 | Shearwater Corporation | Sterically hindered derivatives of water soluble polymers |
| US7960502B2 (en) | 1999-12-22 | 2011-06-14 | Nektar Theapeutics | Sterically hindered poly(ethylene glycol) alkanoic acids and derivatives thereof |
| EP2133098A1 (en) | 2000-01-10 | 2009-12-16 | Maxygen Holdings Ltd | G-CSF conjugates |
| EP1982732A2 (en) | 2000-02-11 | 2008-10-22 | Maxygen Holdings Ltd. | Factor VII or VIIA-like molecules |
| EP2319541A1 (en) | 2000-02-11 | 2011-05-11 | Bayer HealthCare LLC | Factor VII or VIIA-like conjugates |
| US7118737B2 (en) | 2000-09-08 | 2006-10-10 | Amylin Pharmaceuticals, Inc. | Polymer-modified synthetic proteins |
| WO2002049673A3 (en) * | 2000-12-20 | 2003-01-23 | Hoffmann La Roche | Conjugates of erythropoietin (pep) with polyethylene glycol (peg) |
| WO2002049673A2 (en) | 2000-12-20 | 2002-06-27 | F. Hoffmann-La Roche Ag | Conjugates of erythropoietin (pep) with polyethylene glycol (peg) |
| US7128913B2 (en) | 2000-12-20 | 2006-10-31 | Hoffmann-La Roche Inc. | Erythropoietin conjugates |
| EP2080771A2 (en) | 2001-02-27 | 2009-07-22 | Maxygen Aps | New interferon beta-like molecules |
| EP1423093A4 (en) * | 2001-04-23 | 2005-11-30 | Wisconsin Alumni Res Found | MODIFIED HYDROGELS BIFUNCTIONAL |
| US7615593B2 (en) | 2001-04-23 | 2009-11-10 | Wisconsin Alumni Research Foundation | Bifunctional-modified hydrogels |
| US8025901B2 (en) | 2001-04-23 | 2011-09-27 | Wisconsin Alumni Research Foundation | Bifunctional-modified hydrogels |
| WO2003005026A3 (en) * | 2001-07-02 | 2003-06-26 | Amersham Biosciences Uk Ltd | Chemical capture reagent |
| WO2004000366A1 (en) | 2002-06-21 | 2003-12-31 | Novo Nordisk Health Care Ag | Pegylated factor vii glycoforms |
| WO2004012773A1 (en) | 2002-07-24 | 2004-02-12 | F. Hoffmann-La Roche Ag | Polyalkylene glycol acid additives |
| US7504477B2 (en) | 2002-07-24 | 2009-03-17 | Hoffmann-La Roche Inc. | Polyalkylene glycol acid additives |
| US7193031B2 (en) | 2002-07-24 | 2007-03-20 | Hoffmann-La Roche Inc. | Polyalkylene glycol acid additives |
| WO2004022629A3 (en) * | 2002-09-09 | 2004-04-08 | Nektar Therapeutics Al Corp | Method for preparing water-soluble polymer derivatives bearing a terminal carboxylic acid |
| US8784791B2 (en) | 2002-09-09 | 2014-07-22 | Nektar Therapeutics | Method for preparing water-soluble polymer derivatives bearing an N-succinimidyl ester |
| KR100967334B1 (en) | 2002-09-09 | 2010-07-05 | 넥타르 테라퓨틱스 | Process for the preparation of water soluble polymer derivatives with terminal carboxylic acids |
| US7569214B2 (en) | 2002-09-09 | 2009-08-04 | Nektar Therapeutics Al, Corporation | Method for preparing water-soluble polymer derivatives bearing a terminal carboxylic acid |
| US9045494B2 (en) | 2002-09-09 | 2015-06-02 | Nektar Therapeutics | Orthoester compound |
| US8182801B2 (en) | 2002-09-09 | 2012-05-22 | Nektar Therapeutics | Method for preparing water-soluble polymer derivatives bearing a terminal carboxylic acid |
| US8435504B2 (en) | 2002-09-09 | 2013-05-07 | Nektar Therapeutics | Method for preparing water-soluble polymer derivatives bearing a terminal carboxylic acid |
| AU2003270555B2 (en) * | 2002-09-09 | 2009-01-29 | Nektar Therapeutics | Method for preparing water-soluble polymer derivatives bearing a terminal carboxylic acid |
| US8034900B2 (en) | 2002-12-30 | 2011-10-11 | Amylin Pharmaceuticals, Inc. | Water-soluble thioester and selenoester compounds and methods for making and using the same |
| WO2004061094A1 (en) | 2002-12-30 | 2004-07-22 | Gryphon Therapeutics, Inc. | Water-soluble thioester and selenoester compounds and methods for making and using the same |
| EP2390262A1 (en) | 2003-05-16 | 2011-11-30 | Intermune, Inc. | Synthetic chemokine receptor ligands and methods of use thereof |
| EP2263684A1 (en) | 2003-10-10 | 2010-12-22 | Novo Nordisk A/S | IL-21 derivatives |
| EP2407470A2 (en) | 2003-10-14 | 2012-01-18 | F. Hoffmann-La Roche Ltd. | Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication |
| WO2005037214A2 (en) | 2003-10-14 | 2005-04-28 | Intermune, Inc. | Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication |
| EP2633866A2 (en) | 2003-10-17 | 2013-09-04 | Novo Nordisk A/S | Combination therapy |
| EP2641611A2 (en) | 2003-10-17 | 2013-09-25 | Novo Nordisk A/S | Combination therapy |
| US7407973B2 (en) | 2003-10-24 | 2008-08-05 | Intermune, Inc. | Use of pirfenidone in therapeutic regimens |
| US9920106B2 (en) | 2003-12-18 | 2018-03-20 | Novo Nordisk A/S | GLP-1 compounds |
| US7608663B2 (en) | 2004-01-21 | 2009-10-27 | Nektar Therapeutics | Method of preparing propionic acid-terminated polymers |
| US9260472B2 (en) | 2004-02-02 | 2016-02-16 | Ambrx, Inc. | Modified human four helical bundle polypeptides and their uses |
| US8232371B2 (en) | 2004-02-02 | 2012-07-31 | Ambrx, Inc. | Modified human interferon polypeptides and their uses |
| US8906676B2 (en) | 2004-02-02 | 2014-12-09 | Ambrx, Inc. | Modified human four helical bundle polypeptides and their uses |
| US8097702B2 (en) | 2004-02-02 | 2012-01-17 | Ambrx, Inc. | Modified human interferon polypeptides with at least one non-naturally encoded amino acid and their uses |
| US8907064B2 (en) | 2004-02-02 | 2014-12-09 | Ambrx, Inc. | Modified human four helical bundle polypeptides and their uses |
| EP2327724A2 (en) | 2004-02-02 | 2011-06-01 | Ambrx, Inc. | Modified human growth hormone polypeptides and their uses |
| US9175083B2 (en) | 2004-06-18 | 2015-11-03 | Ambrx, Inc. | Antigen-binding polypeptides and their uses |
| WO2006009901A2 (en) | 2004-06-18 | 2006-01-26 | Ambrx, Inc. | Novel antigen-binding polypeptides and their uses |
| US7632924B2 (en) | 2004-06-18 | 2009-12-15 | Ambrx, Inc. | Antigen-binding polypeptides and their uses |
| US7638299B2 (en) | 2004-07-21 | 2009-12-29 | Ambrx, Inc. | Biosynthetic polypeptides utilizing non-naturally encoded amino acids |
| US7947473B2 (en) | 2004-12-22 | 2011-05-24 | Ambrx, Inc. | Methods for expression and purification of pegylated recombinant human growth hormone containing a non-naturally encoded keto amino acid |
| US7858344B2 (en) | 2004-12-22 | 2010-12-28 | Ambrx, Inc. | Compositions of aminoacyl-tRNA synthetase and uses thereof |
| US7939496B2 (en) | 2004-12-22 | 2011-05-10 | Ambrx, Inc. | Modified human growth horomone polypeptides and their uses |
| US7816320B2 (en) | 2004-12-22 | 2010-10-19 | Ambrx, Inc. | Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35 |
| US7959926B2 (en) | 2004-12-22 | 2011-06-14 | Ambrx, Inc. | Methods for expression and purification of recombinant human growth hormone mutants |
| US7883866B2 (en) | 2004-12-22 | 2011-02-08 | Ambrx, Inc. | Compositions of aminoacyl-tRNA synthetase and uses thereof |
| US8163695B2 (en) | 2004-12-22 | 2012-04-24 | Ambrx | Formulations of human growth hormone comprising a non-naturally encoded amino acid |
| US8143216B2 (en) | 2004-12-22 | 2012-03-27 | Ambrx, Inc. | Modified human growth hormone |
| US7829310B2 (en) | 2004-12-22 | 2010-11-09 | Ambrx, Inc. | Compositions of aminoacyl-tRNA synthetase and uses thereof |
| US7838265B2 (en) | 2004-12-22 | 2010-11-23 | Ambrx, Inc. | Compositions of aminoacyl-tRNA synthetase and uses thereof |
| US7846689B2 (en) | 2004-12-22 | 2010-12-07 | Ambrx, Inc. | Compositions of aminoacyl-tRNA synthetase and uses thereof |
| US8178108B2 (en) | 2004-12-22 | 2012-05-15 | Ambrx, Inc. | Methods for expression and purification of recombinant human growth hormone |
| US7736872B2 (en) | 2004-12-22 | 2010-06-15 | Ambrx, Inc. | Compositions of aminoacyl-TRNA synthetase and uses thereof |
| US8178494B2 (en) | 2004-12-22 | 2012-05-15 | Ambrx, Inc. | Modified human growth hormone formulations with an increased serum half-life |
| EP2284191A2 (en) | 2004-12-22 | 2011-02-16 | Ambrx, Inc. | Process for the preparation of hGH |
| US8080391B2 (en) | 2004-12-22 | 2011-12-20 | Ambrx, Inc. | Process of producing non-naturally encoded amino acid containing high conjugated to a water soluble polymer |
| EP2314320A2 (en) | 2005-04-05 | 2011-04-27 | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. | Method for shielding functional sites or epitopes on proteins |
| EP2279756A2 (en) | 2005-04-05 | 2011-02-02 | Instituto di Ricerche di Biologia Molecolare p Angeletti S.P.A. | Method for shielding functional sites or epitopes on proteins |
| US8093356B2 (en) | 2005-06-03 | 2012-01-10 | Ambrx, Inc. | Pegylated human interferon polypeptides |
| EP2360170A2 (en) | 2005-06-17 | 2011-08-24 | Novo Nordisk Health Care AG | Selective reduction and derivatization of engineered proteins comprinsing at least one non-native cysteine |
| WO2006134173A2 (en) | 2005-06-17 | 2006-12-21 | Novo Nordisk Health Care Ag | Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine |
| US7632823B2 (en) | 2005-08-18 | 2009-12-15 | Ambrx, Inc. | Compositions of tRNA and uses thereof |
| EP2045282A1 (en) * | 2005-08-26 | 2009-04-08 | Novo Nordisk A/S | A method of modifying a macromolecular system |
| WO2007022780A1 (en) * | 2005-08-26 | 2007-03-01 | Novo Nordisk A/S | A method of modifying a macromolecular system |
| US7897698B2 (en) | 2005-08-26 | 2011-03-01 | Novo Nordisk A/S | Method of modifying a macromolecular system |
| US9488660B2 (en) | 2005-11-16 | 2016-11-08 | Ambrx, Inc. | Methods and compositions comprising non-natural amino acids |
| EP2093235A1 (en) | 2006-02-08 | 2009-08-26 | Alios Biopharma Inc. | Hyperglycosylated variants of interferon alfacon-1 |
| EP2213733A2 (en) | 2006-05-24 | 2010-08-04 | Novo Nordisk Health Care AG | Factor IX analogues having prolonged in vivo half life |
| US9133495B2 (en) | 2006-09-08 | 2015-09-15 | Ambrx, Inc. | Hybrid suppressor tRNA for vertebrate cells |
| US8022186B2 (en) | 2006-09-08 | 2011-09-20 | Ambrx, Inc. | Modified human plasma polypeptide or Fc scaffolds and their uses |
| US8053560B2 (en) | 2006-09-08 | 2011-11-08 | Ambrx, Inc. | Modified human plasma polypeptide or Fc scaffolds and their uses |
| WO2008030558A2 (en) | 2006-09-08 | 2008-03-13 | Ambrx, Inc. | Modified human plasma polypeptide or fc scaffolds and their uses |
| US8420792B2 (en) | 2006-09-08 | 2013-04-16 | Ambrx, Inc. | Suppressor tRNA transcription in vertebrate cells |
| US8618257B2 (en) | 2006-09-08 | 2013-12-31 | Ambrx, Inc. | Modified human plasma polypeptide or Fc scaffolds and their uses |
| US7919591B2 (en) | 2006-09-08 | 2011-04-05 | Ambrx, Inc. | Modified human plasma polypeptide or Fc scaffolds and their uses |
| EP2548967A2 (en) | 2006-09-21 | 2013-01-23 | The Regents of The University of California | Aldehyde tags, uses thereof in site-specific protein modification |
| US10377805B2 (en) | 2007-03-30 | 2019-08-13 | Ambrx, Inc. | Modified FGF-21 polypeptides comprising non-naturally encoding amino acids and their uses |
| US9517273B2 (en) | 2007-03-30 | 2016-12-13 | Ambrx, Inc. | Methods of treatment using modified FGF-21 polypeptides comprising non-naturally occurring amino acids |
| US9975936B2 (en) | 2007-03-30 | 2018-05-22 | Ambrx, Inc. | Nucleic acids encoding modified FGF-21 polypeptides comprising non-naturally occurring amino acids |
| US11993637B2 (en) | 2007-03-30 | 2024-05-28 | Ambrx, Inc. | Modified FGF-21 polypeptides with non-naturally encoded amino acids |
| US9079971B2 (en) | 2007-03-30 | 2015-07-14 | Ambrx, Inc. | Modified FGF-21 polypeptides comprising non-naturally occurring amino acids |
| US8012931B2 (en) | 2007-03-30 | 2011-09-06 | Ambrx, Inc. | Modified FGF-21 polypeptides and their uses |
| US10961291B2 (en) | 2007-03-30 | 2021-03-30 | Ambrx, Inc. | Modified FGF-21 polypeptides and their uses |
| US8383365B2 (en) | 2007-03-30 | 2013-02-26 | Ambrx, Inc. | Methods of making FGF-21 mutants comprising non-naturally encoded phenylalanine derivatives |
| US8114630B2 (en) | 2007-05-02 | 2012-02-14 | Ambrx, Inc. | Modified interferon beta polypeptides and their uses |
| WO2009067636A2 (en) | 2007-11-20 | 2009-05-28 | Ambrx, Inc. | Modified insulin polypeptides and their uses |
| US8946148B2 (en) | 2007-11-20 | 2015-02-03 | Ambrx, Inc. | Modified insulin polypeptides and their uses |
| EP2930182A1 (en) | 2007-11-20 | 2015-10-14 | Ambrx, Inc. | Modified insulin polypeptides and their uses |
| WO2009093713A1 (en) * | 2008-01-25 | 2009-07-30 | Ebara Corporation | Peg-modified hydroxyapatite, pharmaceutical preparation containing the same as base material, and method for production of the same |
| EP3103880A1 (en) | 2008-02-08 | 2016-12-14 | Ambrx, Inc. | Modified leptin polypeptides and their uses |
| US9938333B2 (en) | 2008-02-08 | 2018-04-10 | Ambrx, Inc. | Modified leptin polypeptides and their uses |
| US9040723B2 (en) | 2008-07-14 | 2015-05-26 | Biocon Limited | Method of synthesizing a substantially monodispersed mixture of oligomers |
| WO2010007626A1 (en) * | 2008-07-14 | 2010-01-21 | Biocon Limited | A method of synthesizing a substantially monodispersed mixture of oligomers |
| US10138283B2 (en) | 2008-07-23 | 2018-11-27 | Ambrx, Inc. | Modified bovine G-CSF polypeptides and their uses |
| EP3225248A1 (en) | 2008-07-23 | 2017-10-04 | Ambrx, Inc. | Modified bovine g-csf polypeptides and their uses |
| WO2010011735A2 (en) | 2008-07-23 | 2010-01-28 | Ambrx, Inc. | Modified bovine g-csf polypeptides and their uses |
| US9121025B2 (en) | 2008-09-26 | 2015-09-01 | Ambrx, Inc. | Non-natural amino acid replication-dependent microorganisms and vaccines |
| US9644014B2 (en) | 2008-09-26 | 2017-05-09 | Ambrx, Inc. | Modified animal erythropoietin polypeptides and their uses |
| US9121024B2 (en) | 2008-09-26 | 2015-09-01 | Ambrx, Inc. | Non-natural amino acid replication-dependent microorganisms and vaccines |
| EP3216800A1 (en) | 2008-09-26 | 2017-09-13 | Ambrx, Inc. | Modified animal erythropoietin polypeptides and their uses |
| US9156899B2 (en) | 2008-09-26 | 2015-10-13 | Eli Lilly And Company | Modified animal erythropoietin polypeptides and their uses |
| US8569233B2 (en) | 2008-09-26 | 2013-10-29 | Eli Lilly And Company | Modified animal erythropoietin polypeptides and their uses |
| US8278418B2 (en) | 2008-09-26 | 2012-10-02 | Ambrx, Inc. | Modified animal erythropoietin polypeptides and their uses |
| US10428333B2 (en) | 2008-09-26 | 2019-10-01 | Ambrx Inc. | Non-natural amino acid replication-dependent microorganisms and vaccines |
| EP2805964A1 (en) | 2009-12-21 | 2014-11-26 | Ambrx, Inc. | Modified bovine somatotropin polypeptides and their uses |
| EP2805965A1 (en) | 2009-12-21 | 2014-11-26 | Ambrx, Inc. | Modified porcine somatotropin polypeptides and their uses |
| EP3815708A1 (en) | 2010-03-05 | 2021-05-05 | Omeros Corporation | Chimeric inhibitor molecules of complement activation |
| WO2011107591A1 (en) | 2010-03-05 | 2011-09-09 | Rigshospitalet | Chimeric inhibitor molecules of complement activation |
| WO2011143274A1 (en) | 2010-05-10 | 2011-11-17 | Perseid Therapeutics | Polypeptide inhibitors of vla4 |
| US10702588B2 (en) | 2010-08-17 | 2020-07-07 | Ambrx, Inc. | Modified relaxin polypeptides comprising a non-naturally encoded amino acid in the A chain |
| WO2012024452A2 (en) | 2010-08-17 | 2012-02-23 | Ambrx, Inc. | Modified relaxin polypeptides and their uses |
| EP4302783A2 (en) | 2010-08-17 | 2024-01-10 | Ambrx, Inc. | Modified relaxin polypeptides and their uses |
| US11786578B2 (en) | 2010-08-17 | 2023-10-17 | Ambrx, Inc. | Modified relaxin polypeptides and their uses |
| US9962450B2 (en) | 2010-08-17 | 2018-05-08 | Ambrx, Inc. | Method of treating heart failure with modified relaxin polypeptides |
| US9567386B2 (en) | 2010-08-17 | 2017-02-14 | Ambrx, Inc. | Therapeutic uses of modified relaxin polypeptides |
| US10751391B2 (en) | 2010-08-17 | 2020-08-25 | Ambrx, Inc. | Methods of treatment using modified relaxin polypeptides comprising a non-naturally encoded amino acid |
| US10253083B2 (en) | 2010-08-17 | 2019-04-09 | Ambrx, Inc. | Therapeutic uses of modified relaxin polypeptides |
| US11439710B2 (en) | 2010-08-17 | 2022-09-13 | Ambrx, Inc. | Nucleic acids encoding modified relaxin polypeptides |
| US8735539B2 (en) | 2010-08-17 | 2014-05-27 | Ambrx, Inc. | Relaxin polypeptides comprising non-naturally encoded amino acids |
| US9452222B2 (en) | 2010-08-17 | 2016-09-27 | Ambrx, Inc. | Nucleic acids encoding modified relaxin polypeptides |
| US11311605B2 (en) | 2010-08-17 | 2022-04-26 | Ambrx, Inc. | Methods of treating heart failure and fibrotic disorders using modified relaxin polypeptides |
| US11273202B2 (en) | 2010-09-23 | 2022-03-15 | Elanco Us Inc. | Formulations for bovine granulocyte colony stimulating factor and variants thereof |
| US12138296B2 (en) | 2010-09-23 | 2024-11-12 | Elanco Us Inc. | Formulations for bovine granulocyte colony stimulating factor and variants thereof |
| WO2013004607A1 (en) | 2011-07-01 | 2013-01-10 | Bayer Intellectual Property Gmbh | Relaxin fusion polypeptides and uses thereof |
| US9382305B2 (en) | 2011-07-01 | 2016-07-05 | Bayer Intellectual Property Gmbh | Relaxin fusion polypeptides and uses thereof |
| EP3088005A1 (en) | 2011-07-05 | 2016-11-02 | biOasis Technologies Inc | P97-antibody conjugates |
| WO2013006706A1 (en) | 2011-07-05 | 2013-01-10 | Bioasis Technologies Inc. | P97-antibody conjugates and methods of use |
| EP3505534A1 (en) | 2012-06-08 | 2019-07-03 | Sutro Biopharma, Inc. | Antibodies comprising sitespecific nonnatural amino acid residues, methods of their preparation and methods of their use |
| WO2013185115A1 (en) | 2012-06-08 | 2013-12-12 | Sutro Biopharma, Inc. | Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
| WO2013189745A3 (en) * | 2012-06-18 | 2014-02-20 | Basf Se | Agroformulations containing a lactone based alkoxylate |
| US9591854B2 (en) | 2012-06-18 | 2017-03-14 | Basf Se | Agroformulations containing a lactone based alkoxylate |
| EP3135690A1 (en) | 2012-06-26 | 2017-03-01 | Sutro Biopharma, Inc. | Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use |
| WO2014022515A1 (en) | 2012-07-31 | 2014-02-06 | Bioasis Technologies, Inc. | Dephosphorylated lysosomal storage disease proteins and methods of use thereof |
| WO2014036492A1 (en) | 2012-08-31 | 2014-03-06 | Sutro Biopharma, Inc. | Modified amino acids comprising an azido group |
| EP4074728A1 (en) | 2012-08-31 | 2022-10-19 | Sutro Biopharma, Inc. | Modified peptides comprising an azido group |
| EP3584255A1 (en) | 2012-08-31 | 2019-12-25 | Sutro Biopharma, Inc. | Modified amino acids comprising an azido group |
| US9579390B2 (en) | 2012-11-12 | 2017-02-28 | Redwood Bioscience, Inc. | Compounds and methods for producing a conjugate |
| US11426465B2 (en) | 2012-11-16 | 2022-08-30 | Redwiid Bioscience, Inc. | Hydrazinyl-indole compounds and methods for producing a conjugate |
| US9310374B2 (en) | 2012-11-16 | 2016-04-12 | Redwood Bioscience, Inc. | Hydrazinyl-indole compounds and methods for producing a conjugate |
| US9833515B2 (en) | 2012-11-16 | 2017-12-05 | Redwood Bioscience, Inc. | Hydrazinyl-indole compounds and methods for producing a conjugate |
| US9605078B2 (en) | 2012-11-16 | 2017-03-28 | The Regents Of The University Of California | Pictet-Spengler ligation for protein chemical modification |
| US10314919B2 (en) | 2012-11-16 | 2019-06-11 | Redwood Bioscience, Inc. | Hydrazinyl-indole compounds and methods for producing a conjugate |
| US10888623B2 (en) | 2012-11-16 | 2021-01-12 | Redwood Bioscience, Inc. | Hydrazinyl-indole compounds and methods for producing a conjugate |
| WO2014160438A1 (en) | 2013-03-13 | 2014-10-02 | Bioasis Technologies Inc. | Fragments of p97 and uses thereof |
| WO2015006555A2 (en) | 2013-07-10 | 2015-01-15 | Sutro Biopharma, Inc. | Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
| EP3336103A1 (en) | 2013-07-10 | 2018-06-20 | Sutro Biopharma, Inc. | Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
| WO2015031673A2 (en) | 2013-08-28 | 2015-03-05 | Bioasis Technologies Inc. | Cns-targeted conjugates having modified fc regions and methods of use thereof |
| WO2015054658A1 (en) | 2013-10-11 | 2015-04-16 | Sutro Biopharma, Inc. | Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use |
| EP4592275A2 (en) | 2013-11-27 | 2025-07-30 | Redwood Bioscience, Inc. | Hydrazinyl-pyrrolo compounds and methods for producing a conjugate |
| WO2015081282A1 (en) | 2013-11-27 | 2015-06-04 | Redwood Bioscience, Inc. | Hydrazinyl-pyrrolo compounds and methods for producing a conjugate |
| US10377806B2 (en) | 2014-10-24 | 2019-08-13 | Bristol-Myers Squibb Company | Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptides and uses thereof |
| US12247058B2 (en) | 2014-10-24 | 2025-03-11 | Bristol-Myers Squibb Company | Nucleic acids encoding modified FGF-21 polypeptides, vectors and cells containing, and use thereof |
| US9631004B2 (en) | 2014-10-24 | 2017-04-25 | Bristol-Myers Squibb Company | Modified FGF-21 polypeptides comprising an internal deletion and uses thereof |
| US9434778B2 (en) | 2014-10-24 | 2016-09-06 | Bristol-Myers Squibb Company | Modified FGF-21 polypeptides comprising an internal deletion and uses thereof |
| US10189883B2 (en) | 2014-10-24 | 2019-01-29 | Bristol-Myers Squibb Company | Therapeutic uses of modified FGF-21 polypeptides |
| US11248031B2 (en) | 2014-10-24 | 2022-02-15 | Bristol-Myers Squibb Company | Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptides |
| US12102689B2 (en) | 2015-11-09 | 2024-10-01 | R.P. Scherer Technologies, Llc | Anti-CD22 antibody-maytansine conjugates and methods of use thereof |
| US12312437B2 (en) | 2016-04-15 | 2025-05-27 | Beckman Coulter, Inc. | Photoactive macromolecules and uses thereof |
| EP4682210A1 (en) | 2016-12-12 | 2026-01-21 | Becton, Dickinson and Company | Water-soluble polymeric dyes |
| US12097242B2 (en) | 2017-02-08 | 2024-09-24 | Bristol-Myers Squibb Company | Treatment of fibrosis, cardiovascular disease and heart failure with modified relaxin polypeptides |
| US11185570B2 (en) | 2017-02-08 | 2021-11-30 | Bristol-Myers Squibb Company | Method of treating cardiovascular disease and heart failure with modified relaxin polypeptides |
| US11364281B2 (en) | 2017-02-08 | 2022-06-21 | Bristol-Myers Squibb Company | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and pharmaceutical compositions thereof |
| US12097241B2 (en) | 2017-02-08 | 2024-09-24 | Bristol-Myers Squibb Company | Methods of treating kidney failure, and/or improving or stablizing renal function using modified relaxin polypeptides |
| US10266578B2 (en) | 2017-02-08 | 2019-04-23 | Bristol-Myers Squibb Company | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof |
| WO2019133399A1 (en) | 2017-12-26 | 2019-07-04 | Becton, Dickinson And Company | Deep ultraviolet-excitable water-solvated polymeric dyes |
| WO2019191482A1 (en) | 2018-03-30 | 2019-10-03 | Becton, Dickinson And Company | Water-soluble polymeric dyes having pendant chromophores |
| WO2020023300A1 (en) | 2018-07-22 | 2020-01-30 | Bioasis Technologies, Inc. | Treatment of lymmphatic metastases |
| EP4389145A2 (en) | 2018-09-11 | 2024-06-26 | Ambrx, Inc. | Interleukin-2 polypeptide conjugates and their uses |
| US12049485B2 (en) | 2018-09-11 | 2024-07-30 | Ambrx, Inc. | Interleukin-2 polypeptide conjugates and their uses |
| WO2020056066A1 (en) | 2018-09-11 | 2020-03-19 | Ambrx, Inc. | Interleukin-2 polypeptide conjugates and their uses |
| WO2020082057A1 (en) | 2018-10-19 | 2020-04-23 | Ambrx, Inc. | Interleukin-10 polypeptide conjugates, dimers thereof, and their uses |
| US12569566B2 (en) | 2019-02-12 | 2026-03-10 | Ambrx, Inc. | Compositions containing, methods and uses of antibody-TLR agonist conjugates |
| WO2020168017A1 (en) | 2019-02-12 | 2020-08-20 | Ambrx, Inc. | Compositions containing, methods and uses of antibody-tlr agonist conjugates |
| WO2021183832A1 (en) | 2020-03-11 | 2021-09-16 | Ambrx, Inc. | Interleukin-2 polypeptide conjugates and methods of use thereof |
| WO2021236526A1 (en) | 2020-05-18 | 2021-11-25 | Bioasis Technologies, Inc. | Compositions and methods for treating lewy body dementia |
| WO2021255524A1 (en) | 2020-06-17 | 2021-12-23 | Bioasis Technologies, Inc. | Compositions and methods for treating frontotemporal dementia |
| WO2022040596A1 (en) | 2020-08-20 | 2022-02-24 | Ambrx, Inc. | Antibody-tlr agonist conjugates, methods and uses thereof |
| WO2022212899A1 (en) | 2021-04-03 | 2022-10-06 | Ambrx, Inc. | Anti-her2 antibody-drug conjugates and uses thereof |
| EP4155349A1 (en) | 2021-09-24 | 2023-03-29 | Becton, Dickinson and Company | Water-soluble yellow green absorbing dyes |
| WO2024007016A2 (en) | 2022-07-01 | 2024-01-04 | Beckman Coulter, Inc. | Novel fluorescent dyes and polymers from dihydrophenanthrene derivatives |
| WO2024044327A1 (en) | 2022-08-26 | 2024-02-29 | Beckman Coulter, Inc. | Dhnt monomers and polymer dyes with modified photophysical properties |
| WO2024196805A1 (en) | 2023-03-17 | 2024-09-26 | Beckman Coulter, Inc. | Benzothienopyrrole cyanine dyes |
| WO2025064842A1 (en) | 2023-09-21 | 2025-03-27 | Beckman Coulter, Inc. | Dihydrophenanthrene (dhp) bridged dyes for use in flow cytometry |
| WO2026043823A2 (en) | 2024-08-19 | 2026-02-26 | Sutro Biopharma, Inc. | Antibodies comprising site-specific non-natural amino acid residues, methods of preparation and uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| US5672662A (en) | 1997-09-30 |
| AU6345796A (en) | 1997-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5672662A (en) | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications | |
| KR100948532B1 (en) | Branched polymers and conjugates thereof | |
| KR100499655B1 (en) | Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation | |
| US5990237A (en) | Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines | |
| US10385165B2 (en) | N-maleimidyl polymer derivatives | |
| US8183338B2 (en) | Sterically hindered poly(ethylene glycol) alkanoic acids and derivatives thereof | |
| US7193031B2 (en) | Polyalkylene glycol acid additives | |
| US5414135A (en) | Vinyl sulfone coupling of polyoxyalkylenes to proteins | |
| US8299173B2 (en) | Method involving 1-benzotriazolyl carbonate esters of polymers | |
| US20040115165A1 (en) | Bifunctional polyethylene glycol derivatives | |
| US20060155059A1 (en) | Polyethylene (glycol) derivatives with proximal reactive groups | |
| WO1997014740A1 (en) | Discrete-length polyethylene glycols | |
| JPH10505088A (en) | Polysaccharides, polypeptides (proteins) and electrophilic polyethylene oxides for surface modification | |
| US20100063328A1 (en) | Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation | |
| US6916962B2 (en) | Monofunctional polyethylene glycol aldehydes | |
| US6956135B2 (en) | Monofunctional polyethylene glycol aldehydes | |
| US7041855B2 (en) | Monofunctional polyethylene glycol aldehydes | |
| US20030153694A1 (en) | Novel monofunctional polyethylene glycol aldehydes | |
| KR20220069994A (en) | Asymmetric branched degradable polyethylene glycol derivatives | |
| Braunová et al. | Degradation behavior of poly (ethylene glycol) diblock and multiblock polymers with hydrolytically degradable ester linkages | |
| US20070141021A1 (en) | Methylmaleimidyl polymer derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AT AU AZ BB BG BR BY CA CH CN CZ CZ DE DE DK DK EE EE ES FI FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: CA |